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Abstract
MODULATING THE INNATE IMMUNE RESPONSE TO ELECTROSPUN
SCAFFOLDS AND POLYMER DEGRADATIVE BYPRODUCTS
By Daniel Abebayehu, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Biomedical Engineering at Virginia Commonwealth University.
Virginia Commonwealth University, 2017
Director: JOHN J. RYAN, PH.D.
Professor, Biology

Implanted biomaterials often induce inflammation that frequently leads to the foreign
body response, fibrosis, and the failure of the implant. Thus, it is important to evaluate
how cells interact with materials to promote a more regenerative response. It is critical to
determine how to modulate the response of tissue resident innate immune cells, as they
are among the first cells to interact with implanted materials. Among tissue resident
innate immune cells are mast cells, which are inflammatory sentinels that degranulate and
orchestrate the fate of other cell populations, such as monocytes/macrophages and

lymphocytes. Mast cells have also been reported to play a vital role in the foreign body
response of implanted biomaterials as well as angiogenesis. The goal of this study was to
determine how to modulate mast cell responses to electrospun scaffolds by altering
scaffold architecture and composition to promote anti-inflammatory and regenerative
cell-scaffold interactions. Scaffold architecture was manipulated by changing either fiber
diameter or pore diameter and mast cell responses were mediated by endogenous and
exogenous DAMPs (i.e. IL-33 and LPS, respectively). Particularly in response to IL-33,
scaffolds with increased fiber and pore diameter promoted less inflammatory cytokine
and chemokine release while increasing angiogenic cytokine release. Additionally, taking
scaffolds that promoted increased inflammatory cytokine expression and increasing the
pore diameter alone dampened inflammatory cytokine expression. The next question we
wanted to answer was how might the degradative byproducts of scaffolds alter mast cell
inflammatory responses. Given the widespread use of polylactic acid, we decided to
investigate this question using lactic acid as a degradative byproduct. In the presence of
physiologically relevant levels of lactic acid, IL-33- and IgE-mediated inflammatory
cytokines and chemokines are suppressed, while angiogenic cytokines are enhanced. This
response was shown to be pH- and MCT1-dependent and was recapitulated in primary
human skin mast cells as well as in vivo. In summary, scaffold architecture and the
presence of select polymer degradative byproducts have the potential of selectively
suppressing inflammatory cytokines and enhancing angiogenic cytokines.

CHAPTER I: INTRODUCTION
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I.1 HISTORICAL OVERVIEW
The stories of immunology and regenerative medicine are inextricably linked,
dating back to ancient civilizations, where people used therapies that promoted healing
and repair without knowing that these interventions manipulated the immune response.
For example, people in ancient Egypt used honey as a wound dressing because it
accelerated healing of burns and various dermal wounds, which is partially due to
honey’s ability to enhance neutrophil infiltration, lymphocyte proliferation, MMP
activation, and growth of granulation tissue (1). In 2500 BC, Suśrata, widely considered
the father of Surgery, operated on patients with autologous gluteal skin grafts, which
would have had a higher rate of rejection by the immune system had they not been
autografts. The Mayans were noted to have used nacre shell as a dental implant, which
requires a balance of enhancing sufficient bone formation and reducing activity of
osteoclasts, bone-resident macrophages (2). Interestingly, one of the most noteworthy
pieces of art within the context of tissue engineering is the Healing of Justinian, which
features an early portrayal of homograft transplantation (2-4).
Moving forward in history, immunology and regenerative medicine can also trace
their common history back to the age of the Enlightenment, when the observable world
was no longer explained exclusively by spiritual or metaphysical truths but by empirical
observations. Many of these observations were early discoveries that led to the
development of the Cell Theory. In 1665, while looking at cross-sections under a
microscope, Robert Hooke first coined the term “cell” or cella, which is latin for “small
room”. While his seminal work Micrographia is widely considered to be the advent of
microscopy, it is also considered to be the genesis of cell biology (5). From there,
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German botanist Matthias Schleiden and German physiologist Theodor Schwann made
two critical observations in 1838 and 1839 that would serve as the foundation of Cell
Theory: 1) all living organisms are made of cells and 2) the cell is the basic unit of all
living organisms (6). The final tenet of Cell Theory was provided by Rudolf Virchow,
who in 1858 published a work entitled Cellular Pathology where he wrote omnis cellula
e cellula, “every cell comes from another cell”. Virchow’s critical observation that cells
only come from preexisting cells is critical to cell biology, and particularly for fields such
as hematology and stem cell biology (7, 8). The early findings that formulated the Cell
Theory lay the foundation for all the following work done in the fields of immunology
and regenerative medicine.
An important note to make is that while the success of early therapies that
promoted healing and tissue growth can be partially attributed to the immune response, so
are many failures. While the two fields have similar origin stories, it is worth taking a
closer look at each of their respective histories to better appreciate their current states and
what the future holds.

I.3 HISTORY OF IMMUNOLOGY
Since early civilizations, people have acknowledged that exposure to pathogens
like smallpox conferred protection against subsequent exposures, though not in those
words. Those who had survived smallpox were called upon to nurse the afflicted. As
awareness grew of the propensity of previously affected individuals to be protected from
further infection, some started to inoculate themselves with the smallpox virus. They
would give themselves nasal or subcutaneous exposures to smallpox with fluid from the
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blisters of infected individuals. This crude form of vaccination was largely effective, but
the dawn of vaccination came with Edward Jenner. As an apprentice to a town surgeon
and during his time as a physician, Jenner noticed that milkmaids who had previously
contracted cowpox were resistant to becoming infected with smallpox. Based on his
observations, Jenner hypothesized that cowpox could confer protection against smallpox,
which he proved to be true by vaccinating a young boy with fluid from the blisters a
milkmaid who had just contracted cowpox. Jenner then subsequently exposed the boy to
smallpox, and ten days later the boy had no infection. A second challenge occurred two
months later with smallpox and the boy had developed no disease (9).
This work was advanced further by the contributions of Louis Pasteur, who
noticed similar responses among chickens with fowl cholera. But his contributions to
vaccinations came to fruition when he began to expand his work to develop a vaccination
for anthrax. Interestingly, after reporting his discovery of a vaccine against anthrax for
cattle, Pasteur was challenged to treat cattle before a crowd of people. Of course, he
accepted. Each of the cattle that received the vaccine with the attenuated bacteria
survived subsequent active anthrax challenge, while all the cattle in the control group
died. His work also led to the development of a vaccine against rabies, discrediting the
spontaneous generation theory based on his work with fermentation, and developing the
germ theory to explain infection disease (10).
While Pasteur’s work garnered him the title as the “father of immunology”, the
arrival of the 20th century brought with it the discoveries that comprise modern
immunology. The next person to push the field of vaccines and immunization further was
Paul Ehrlich. He was the first to bring together different observations and conceptualize
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active and passive immunization. He pioneered many different techniques within the field
of histology and used those new methods in staining to be the first to identify mast cells,
basophils, eosinophils, and neutrophils. And if all of that was not impressive enough,
Ehrlich postulated the “side chain theory”, which consisted of a hypothesis that receptors
were present that would bind specific toxins on cells and could also be released and bind
toxins as an antitoxin, or an antibody. This theory would be the last piece of Ehrlich’s
body of work that helped him win the 1908 Nobel Prize in medicine (11-13).
Ehrlich shared his award with Elie Metchnikoff, a Russian scientist who proposed
an alternative theory to characterize immunology. While Ehrlich proposed that
immunology entailed antitoxins and responses to specific toxins, Metchnikoff proposed
that host defense consisted of phagocytic cells ingesting invading pathogens (14).
Interestingly, Ehrlich’s theory became the basis for adaptive immunity, while
Metchnikoff’s phagocytic cell theory is the basis of innate immunity. Figure 1.1 shows
the two arms of the immune system that these two men hypothesized over a century ago.
The ability of the immune system to recognize foreign antigens and non-self tissue, as
well as phagocytize those foreign substances, has had major repercussions on different
fields but particularly on organ and tissue transplantation. Interestingly, organ and tissue
transplantations were the early forms of tissue engineering. The introduction of tissue
engineering was meant to help address the rising need for more organ and tissue donors,
with no changes in the supply. Throughout history, the idea to engineer new organs and
tissue was always present but did not fully materialize until the late 20th century.
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FIGURE 1.1 Adaptive and Innate Immunity (15) The innate immune system consists
of various granulocytes, such as basophils, eosinophils, and neutrophils, as well as
macrophages, dendritic cells, macrophages, and mast cells. The adaptive immune
response consists of antibody producing B cells and key effector T cells. There also exists
a group of adaptive immune cells that bear non-specific characteristics that make them
innate-like lymphocytes, such as γδ T cells and NK T cells.
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I.3 HISTORY OF TISSUE ENGINEERING & REGENERATIVE MEDICINE
While the use of the terms “tissue engineering” and “regenerative medicine” only
sprang up in the 20th century, the concepts have existed for much longer. Dating back to
Ancient Greece, the legend of Prometheus tells of a man whose liver would undergo
regeneration on a daily basis (2). In the book of Genesis in the Old Testament, we read
that Eve was made, or “engineered”, from a rib taken from the side of Adam (3). Lastly,
we read in Mary Shelley’s 1818 novel Frankenstein the story of a scientist who engineers
a living creature out of tissues from corpses (4). Each of these stories demonstrates a
historical precedent for our fascination with the regeneration of human tissues.
While the above stories are fictional, biblical, or mythological, the early forms of
tissue engineering and regenerative medicine in reality were pioneering studies and
observations in tissue grafting (e.g. autologous and allograft), and organ transplantation.
One of the key early studies that demonstrated real regeneration was done by Abraham
Trembley, who in 1744 reported the ability of severed polyps to totally regenerate after
resecting samples into different lengths and numbers of pieces. In 1817, Christian Pander
proposed a critical relationship between cells and the microenvironment they inhabit (2).
Around this same time, some of the earliest studies investigating skin graft
transplantation were underway. Johann Friedrich Dieffenbach wrote a doctoral thesis
entitled Nonnulla de Regeneratione et Transplantatione (meaning “some of regeneration
and transplantation”) that explored suitable skin grafts from various sources on birds and
mammals. His work failed once he switched to the human system, but others who
followed in his footsteps, including Heinrich Christian Bünger, Jaques Reverdin, and
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Karl Thiersch, expounded on Dieffenbach’s findings and helped us to better understand
skin graft transplantation in humans (4).
In 1910, Ross Harrison was the first to accomplish ex vivo tissue growth.
However, his discovery was furthered by Alexis Carrel, who designed a tissue culture
system for expanding large numbers of ex vivo cells. This work is the foundation for
modern tissue culture techniques today. Carrel continued to press on and worked with the
famous aviator Charles Lindbergh to develop a perfusion pump (i.e. the Lindbergh Pump)
that kept ex vivo tissue viable for 1-2 months after harvesting. This pump would become
a monumental contribution to whole organ transplantation and open-heart surgery (2).
Much of early tissue engineering was focused on facilitating tissue and organ
transplantation. Due to limitations on sourcing, there arose a need for an alternative to
patients waiting for tissues and organs to become available. This need led to the advent of
modern tissue engineering.
Early modern tissue engineering history brings us into the mid-20th century, where
Dr. James Till and colleagues discovered that there existed hematopoietic cells that could
differentiate into various lineages in the spleen (16). These findings served as the
introduction into stem cells and stem cell biology. Nearly concurrent with the discovery
of stem cells, Judah Folkman at Harvard’s Children’s Hospital was making great strides
in tissue differentiation and organization, and his most notable work in tumor
angiogenesis. This had great bearing on our understanding of the vascularization of
nearly all tissues. One of Judah Folkman’s trainees would later go on to study the
interplay between cells and stem cells and their response to mediators that would promote
new tissue formation on engineered substrates. That trainee was Robert Langer, who in
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collaboration with Joseph Vacanti from Massachusetts General Hospital published the
seminal 1993 paper that first introduced the term “tissue engineering” (17). Interestingly,
that was not the first time the term “tissue engineering” was used. A paper investigating
the outcome of corneal prosthetics first published the term describing the importance of
prosthetic integration with native tissue via the formation of a new, integrating membrane
(18). However, the Langer and Vacanti paper popularized the term and established the
paradigm for the field.
Tissue engineered therapies consist largely of some combination of these three
elements:
1) Cells, whether progenitor/stem cells or fully differentiated, that will be the
basis for the desired tissue
2) Growth factors or other mediators that help inform how tissue develops
3) Scaffolds or some structure that either provides the architecture for the desired
tissue or is simply a delivery mechanism (17).

In addition to laying out the principles of tissue engineering, Vacanti later published a
strikingly unforgettable example of how successful tissue engineering therapies can be
when they employ some combination of the principles mentioned above. Briefly, a
polyglycolyic acid polymer structure was designed in the shape of a 3-year-old patient’s
outer ear, the structure was then seeded with chondrocytes, and then implanted
subcutaneously in athymic mice. In short, the implant produced new cartilage formation
subcutaneously, maintained its structure throughout the implantation period, and closely
resembled the histological properties of a native ear. This work produced what has now
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been dubbed the “Vacanti mouse”, which is illustrated in Figure 1.2 (19). Ever since the
Langer and Vacanti paper, scientists have been engineering therapies for nearly every
major tissue imaginable. As new avenues are explored and new questions posed, new
obstacles arise. One obstacle that is nearly a ubiquitous problem throughout all of tissue
engineering and biomaterial design is overcoming the initial immune response and the
subsequent inflammation becoming chronic. Therefore it is important to better
understand the mediators present in response to initial tissue injury, the phases of wound
healing, and what biomaterials should be doing in that context.
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FIGURE 1.2 The “Vacanti mouse” (19) In this seminal study, synthetic polymer
scaffolds were fabricated in the shape of the human outer ear, seeded with chondrocytes,
and then implanted subcutaneously into athymic nude mice. This was a key study
demonstrating the potential of tissue engineered therapies.

11

I.4 TISSUE INJURY AND RESPONSE TO BIOMATERIALS
In order to better understand how to improve healing, it is critical to understand
what occurs during injury. The mediators that are released in response to tissue injury or
are required for healing include factors unique to certain tissues, however, much of the
steps that take place are common to many tissues, as displayed in Figure 1.3. In response
to tissue damage or simply the implantation of a biomaterial, there are initial interactions
with the blood that prompt protein adsorption to the surface of the implant. Next, platelet
aggregation occurs causing coagulation and the formation of a provisional fibrin matrix.
This matrix serves as an early endogenous scaffold that mediates cell migration as well as
biochemical signals (20). The source of the biochemical signals present on the
provisional matrix is platelets, which release the contents of their granules when
aggregated. The contents of platelet granules consist of von Willebrand factor (vWf),
transforming growth factor β-1 (TGF β-1), platelet derived growth factor (PDGF),
fibronectin, vascular endothelial growth factor (VEGF), basic fibroblast growth factor
(bFGF), stromal cell-derived factor-1α (SDF-1α), IL-10, monocyte chemotactic protein-1
(MCP-1), macrophage inflammatory protein-1 (MIP-1α), tumor necrosis factor (TNF),
and IL-1β (21, 22). Simultaneous to the formation of a provisional matrix, tissue damage
elicits the release of several different endogenous mediators in the tissue
microenvironment (TME), which include, but are not limited to, IL-33, high mobility
group box 1 (HMGB1), IL-1α, heat shock proteins (HSP), and reactive oxygen species.
Exogenous signals include pathogen associated molecular patterns (PAMPs), such as
lipopolysaccharide (LPS) (23). IL-33, HMGB1, IL-1α, and heat shock proteins (HSP)
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FIGURE 1.3 Tissue Injury and Wound Healing (24) The wound healing cascade is a
spatio- and temporally-controlled process that includes early phases of hemostasis and
recruitment of innate immune cells that dictate local inflammation. In response to factors
released by platelets, macrophages, and mast cells, granulation tissue arises to
revascularize and restructure the local environment. Controlled inflammation and ECM
deposition promotes healing, whereas chronic inflammation and aberrant ECM
deposition leads to poor healing and scarring.
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serve as alarmins that signal the occurrence of tissue damage and prompt robust
inflammatory signaling (25). The cells that respond to these newly present alarmins are
tissue-resident innate immune cells, which chiefly consist of macrophages and mast cells.
Macrophages and mast cells are innate immune cells that mature once they migrate into
the peripheral tissue and carry out various functions. Macrophages play a significant role
in responding to intracellular pathogens, microbial products, and perform phagocytosis.
Mast cells are critical sentinel cells that respond to parasitic infections and are critical in
atopic disease. While distinct in those various functions, both cell populations respond to
damage signals. In response to the milieu of factors now present, tissue-resident innate
immune cells release a myriad of inflammatory factors.
It is important to take a moment and acknowledge how macrophages and mast
cells respond to these different stimuli. Upon activation, macrophages can commit to a
polarized state, either M1 or M2. The anti-inflammatory M2 phenotype, which was
traditionally defined by their IL-4 and IL-13 induction (now referred to as M2a), has
recently been further expanded to include more subsets, depending on the stimulus. The
other stimuli that can prompt one of the M2 subsets (i.e. M2b, M2c, or M2d) are IL-10,
glucocorticoids, immune complexes, TGFβ-1, and IL-6. The inflammatory M1
phenotype is triggered in the presence of TNF, lipopolysaccharide (LPS), or interferon-γ
(IFNγ). Figure 1.4 illustrates the different macrophage phenotypes, what initiates their
polarization, and the factors they produce. Many of these polarizing signals become
present shortly after tissue injury or biomaterial implantation. It is important to note that
macrophages do not permanently commit to one of the polarized states, and that the local
macrophage population does not homogenously commit to one polarization. More
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FIGURE 1.4 Macrophage polarization (26) Naïve macrophages undergo polarization
depending on the factors present in the local microenvironment. Macrophage polarization
is both plastic and exists on a spectrum, where each phenotype plays a key role in various
context and pathologies. While the human system is not totally analogous to murine
macrophage polarization, the key phenotypes of M2 macrophages being antiinflammatory and M1 macrophages being pro-inflammatory holds true.
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inflammatory conditions will promote more M1 macrophages, and conditions that are
resolving inflammation and promoting repair will have a greater M2 macrophage
presence. Interventions should be focused on changing the balance of macrophage
polarization (26). While our work is not focused on determining macrophage
responsiveness and polarization, this process is critically important for tissue homeostasis
and resolving inflammation (27, 28). Interestingly, the alarmins and mediators released
during hemostasis can trigger some of these macrophage-polarizing factors to be released
via mast cell activation.
Previous work has demonstrated that a key mast cell activating agent in the
context of cell injury is IL-33 (23). It was not until 2005 that the receptor for IL-33 was
discovered to be ST2, before which ST2 was referred to as an orphan receptor (29).
Despite the fairly recent pairing of IL-33 and ST2, there has been study of IL-33
activation in mast cells. In response to IL-33 ST2 signal transduction elicits release of
various pro-inflammatory cytokines, chemokines, and eicosanoids (30). The IL-33
signaling pathway is illustrated in Figure 1.5. IL-33 also promotes mast cell survival,
adhesion, and maturation (31-34). Prior to pairing IL-33 with ST2, it was previously
referred to as nuclear factor-high endothelial venules and is largely expressed at the
protein level in the nucleus of structural cell populations, such as endothelial cells,
epithelial cells, fibroblasts, keratinocytes, and airway smooth muscle cells (34). While in
the nucleus, IL-33 has surprisingly been shown to be capable of suppressing
inflammatory signaling by hindering NF-κB-mediated transcription (35). Despite that
anti-inflammatory role, the ability of IL-33 to activate mast cells elicits a strong pro-
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FIGURE 1.5 IL-33 Signaling Pathway in mast cells IL-33 binds to its receptor, ST2,
and as a member of the IL-1 family, it’s receptor co-associates with IL-1Rap (IL-1
receptor-associated protein. Additionally, ST2 and IL-1Rap co-associate with c-Kit to
form a complex upon IL-33 binding ST2, leading to signaling events downstream of cKit that have been shown to be critical for IL-33 signaling. IL-33 activation leads to
downstream phosphorylation of MAPK and NF-κB, leading to transcription and
production of inflammatory cytokines and chemokines.

17

inflammatory response. Mast cell activation by IL-33 has also been shown to promote
TNF-mediated neutrophil recruitment (36).
After the responses of tissue-resident cells, neutrophils are among the first cell
populations recruited to the injury or implanted biomaterial. Their role as currently
understood involves clearing debris, releasing matrix metalloproteinases (MMP) and
inflammatory reactive oxygen species (ROS), and releasing chemoattractants that
mediate the recruitment of other cells (20). Among the cells that neutrophils recruit are
more macrophages that can be polarized to M1 or M2 phenotypes. As macrophages,
neutrophils, and mast cells secrete factors altering innate immune cell recruitment, their
response, coupled with platelet activation also promotes fibroblast and endothelial cell
recruitment. As the proteases that have been released clear space for cell recruitment,
fibroblasts begin laying down new collagen while endothelial cells strive to revascularize
the area, creating granulation tissue (20, 37).
It is at this point that two divergent fates emerge. The favorable fate consists of
sufficient vascularization of the local microenvironment, implant integration with the
local tissue, deposition of new ECM proteins that resemble the native tissue, and
production of the necessary factors unique to that tissue for de novo functional tissue
formation. The pathological fate, which is the case for many implanted biomaterials,
consists of aberrant collagen deposition and myofibroblast differentiation, indicative of a
fibrotic response. Next, the inability of macrophages to engulf the material can lead to
“frustrated phagocytosis”, where macrophages begin to fuse together to form
multinucleated foreign body giant cells (FBGCs) (38). FBGC development and aberrant
collagen production culminate into a collagenous fibrotic capsule closing off the implant
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from surrounding tissue, rendering it ineffective and unable to perform the intended
function. This foreign body response is of great concern to biomaterial design and
requires novel approaches. Recent work has shown that biomaterials implanted into mast
cell-deficient animals were subjected to a more severe foreign body response than the
wild type mouse, indicating a role for mast cells to be explored in addressing this
pathology (39). There is a need to better understand how early signals from mast cells can
control inflammation to prevent chronic inflammation and fibrosis. More specifically,
based on the work showing that IL-33 is the primary activating mediator of mast cells
during cell injury, more work needs to be done investigating how IL-33 activation of
mast cells can be modulated in response to biomaterials and their various features.
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CHAPTER II: ALTERED STRUCTURE OF
ELECTROSPUN SCAFFOLDS PROMOTES
DIFFERENT PHENOTYPES OF INNATE IMMUNE
CELLS

20

II.1 ABSTRACT
Implanted scaffolds often induce inflammation that frequently leads to the foreign
body response (FBR), fibrosis, and the failure of the scaffold. Thus, it is important to
evaluate how cells interact with the scaffolds to promote a more regenerative response.
Our group has recently demonstrated that macrophage phenotype can be modulated by
the fiber diameter and pore size of an electrospun scaffold. However, it is critical to
determine how to modulate the response of other tissue resident innate immune cells.
Mast cells are inflammatory sentinels that degranulate and orchestrate the fate of other
cell populations, such as monocytes/macrophages and lymphocytes. Mast cells have also
been reported to play a vital role in the FBR of implanted biomaterials as well as
angiogenesis (39-47). The goal of this study was to determine how to modulate mast cell
responses to electrospun scaffolds of varying fiber diameter and porosity in order to
promote anti-inflammatory and regenerative cell-scaffold interactions. Murine bone
marrow-derived mast cells (BMMC) were cultured on 10mm disks composed of
electrospun polydioxanone (PDO) scaffolds. Scaffolds were either made from a 60
mg/mL polydioxanone solution, which yielded a scaffold with a pore diameter of 1.5 μm
and fiber diameter of 400 nm, or a 140 mg/mL polydioxanone solution, which yielded a
scaffold with a pore diameter of 18 μm and fiber diameter of 2.4 μm. Scaffolds were
coated with fibronectin to promote mast cell adhesion and incubated with mast cells for
48 hours, followed by IL-33- or LPS-mediated activation. Relative to the 60 mg/mL
scaffold, the 140 mg/mL scaffold promoted significantly less inflammatory cytokines to
be released, while enhancing VEGF secretion. This corroborates the previous findings
with macrophages, showing that altering scaffold structure alone is capable of altering
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innate immune cell interactions. The changes in cytokine levels were also present at the
mRNA level as well. When pore size was increased on the 60 mg/mL scaffold using an
air-flow mandrel, inflammatory cytokine production went down. Surprisingly, decreasing
the pore size of the 140 mg/mL scaffold only partially elevated inflammatory cytokine
production, indicating a possible role for fiber diameter in addition to pore size in altering
innate immune cell interactions. All together, this demonstrates that LPS- and IL-33mediated mast cell responses to electrospun scaffolds can be modulated by altering
scaffold architecture.

II.2 INTRODUCTION
Biomaterials are characterized as materials engineered for therapeutic or
diagnostic purposes by interacting with living organisms (20). For any implanted
biomaterial, an important limitation to consider is the immune response and how to
mitigate inflammation. Upon implantation, a cascade of events is initiated that often leads
to unresolved inflammation, frustrated phagocytosis, and macrophage fusion to form
foreign body giant cells. This leads to fibrosis, with the biomaterial being encapsulated
with a fibrotic capsule. This outcome contributes to implant failure and persistent pain
among patients (38, 48-51). However, the mechanism by which the immune response can
be modulated by polymer scaffold design has yet to be fully determined. Innate immune
cells are understood to determine the fate of implanted biomaterials (52). Of innate
immune cells, two key tissue-resident populations are macrophages and mast cells.
Macrophages are a heterogeneous cell population that plays a major role in innate
immunity. Their inactive phenotype (MØ) is converted to a pro-inflammatory (M1) or an
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angiogenic/regenerative phenotype (M2) by the microenvironment, with great plasticity
(53). Macrophages originate in the bone marrow from the common myeloid progenitor
cell, and mature until exiting the marrow as a blood monocyte. Monocytes differentiate to
their mature macrophage form upon entering tissues (54). Macrophages are crucial for
tissue homeostasis, pathogen clearance, inflammation resolution, angiogenesis, and
wound healing (55). Their role as a key phagocytic cell is part of why macrophages play
an important part in implant fate. As a phagocyte, macrophages engulf cellular debris
during implant-induced tissue remodeling, and directly interact with the implant. The
regenerative capacity of a scaffold can be dictated by macrophage phenotype and activity
(growth factor/cytokine secretion), especially the ability to promote macrophagemediated angiogenesis/tissue regeneration (49). Macrophages can also be influenced by
the response to an implant from other tissue resident immune cells, such as the mast cell.
Mast cells are another innate immune cell that have been shown to play an
essential role in wound healing, inflammation, angiogenesis, tissue remodeling, and the
foreign body response (56). Similar to macrophages, mast cells originate in the bone
marrow from the common myeloid progenitor, move to the vasculature as a mast cell
progenitor, and fully mature in the tissue. Mast cells are widely present throughout the
body and have been extensively studied in the context of allergic disease (57, 58).
However, recent findings have expanded the importance of mast cells in other contexts,
including vascularization (47). When angiogenesis occurs during remodeling, it is
preceded or accompanied by macrophage and neutrophil influx that has been shown to be
mast cell-mediated (59). Once activated, mast cells produce myriad factors, including
transforming growth factor (TGF-β1), fibroblast growth factors (FGF-1 and FGF-2),
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interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF) (60). Since mast
cells and macrophages clearly play a pivotal role in inflammatory and remodeling/wound
healing responses, scaffolds should be engineered to modulate their behavior. Biomaterial
implants designed to suppress inflammation and promote wound healing will have a
greater capacity for regeneration, yielding improved vascular prosthetics.
One hypothesized way of controlling innate immune cell responses to electrospun
scaffolds is to alter the architecture of the implant. There has been considerable work
exploring how altering scaffold pore size can influence implant function and success
(48). Altering pore size in engineered structures can influence both angiogenesis and
macrophage polarization (61). Additionally, scaffold fiber diameter changes affect
inflammatory cytokine production (62). Our group has previously published that
increasing scaffold pore size and fiber diameter promotes macrophage M2 polarization
(38). While the findings with macrophages are important and will help improve
biomaterial design, macrophages are not the only immune cell population that need to be
studied in relation to scaffold interactions. Very little work has assessed how mast cells
respond to scaffolds, despite the important role mast cells play in inflammation, wound
healing, and angiogenesis (46, 63, 64). This next chapter describes studies investigating
how scaffold structure can alter mast cell responses. Mouse bone marrow-derived mast
cells (BMMC) were cultured on scaffolds of varying morphologies and activated with
either LPS or IL-33, to mimic mediators present during tissue damage.

II.3 MATERIALS AND METHODS
II.3.1 Electrospinning

24

Electrospinning was used to create fibrous scaffolds of various morphologies
made from polydioxanone (Ethicon Inc.). Polydioxanone was dissolved in 1,1,1,3,3,3,
Hexafluoro-2-isopropanol (HFP) at either 60 or 140 mg/mL in a scintillation vial. The
polymer solutions were then aspirated into Becton Dickinson 5mL syringes with 18
gauge blunt tip needles. The syringe was then loaded into a KDS 100 Legacy Syringe
Pump (KD Scientific) and the polymer solution was dispensed at a 6 mL/hr. Polymer
solutions were electrospun across a gap distance of 12 cm onto stainless steel rotating
rectangular mandrels (0.5 cm x 3 cm 1.5 cm) or onto a perforated air-flow mandrel with
an inlet pressure of 50 kPa. All scaffolds were electrospun with an applied voltage of
25kV and mandrels rotating at a speed of 400 rpm. After electrospinning, scaffold
samples were imaged using a JEOL JSM-5610LV scanning electron microscope.
Scanning electron micrographs were analyzed to measure fiber diameter and pore
diameter using ImageJ.

II.3.2 Reagents
Recombinant mouse IL-3, SCF, and IL-33, as well as mouse IL-6, TNF, and
MCP-1 (CCL-2) ELISA kits were purchased from BioLegend (San Diego, CA). Mouse
MIP-1α (CCL-3) and VEGF ELISA kits were purchased from PeproTech (Rocky Hill,
NJ). Lipopolysaccharide (LPS) from Escherichia coli 055:B5 was purchased from SigmaAldrich (cat no. L4524, St. Louis, MO).

II.3.3 Cell culture and cell seeding
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Following electrospinning, 10mm disks were produced using biopsy punches and
disinfected by soaking in 70% ethanol for 15 minutes and washing twice with 1X PBS.
To promote mast adhesion, scaffold disks were incubated in fibronectin at 50 μg/mL for
1 hour at 37°C. After incubation, scaffolds were moved to a new well to avoid residual
fibronectin. BMMC were developed by harvesting bone marrow from the tibias and
femurs of euthanized C57BL/6 mice. Following harvesting, bone marrow was cultured
for 3 weeks in complete RPMI (cRPMI) 1640 medium (Invitrogen Life Technologies,
Carlsbad, CA) containing 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin, 1mM sodium pyruvate, and 1mM HEPES (all from Corning, Corning,
NY), supplemented with IL-3-containing supernatant from WEHI-3B cells and SCFcontaining supernatant from BHK-MKL cells. The final concentrations of IL-3 and SCF
were adjusted to 1.5ng/ml and 15ng/ml, respectively, as measured by ELISA. BMMC
were used after 3 weeks of culture, at which point these primary populations were >90%
mast cells, based on staining for c-Kit and FcεRI expression. BMMC were seeded at
1x106/mL on fibronectin-coated scaffolds with a cloning ring to concentrate the cells on
the scaffold in cRPMI with IL-3 and SCF at 10 ng/mL. After 48-hour incubation on
fibronectin-coated scaffolds, IL-33 (100 ng/mL) or LPS (1 μg/mL) was added to activate
cells.

II.3.4 qPCR
BMMC were seeded on scaffolds and activated with 100 ng/mL of IL-33 for 6 hours.
Scaffolds were then placed in TRIzol reagent (Life Technologies, Grand Island, NY) to
extract RNA, which was measured using a Thermo Scientific NanoDrop 1000 UV-vis
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Spectrophotometer (Thermo Scientific, Watham, MA). cDNA was produced using
qScript cDNA Synthesis Kit from Quanta Biosciences (Gaithersburg, MD), and amplified
using PerfeCTa SYBR Green SuperMix (QuantaBio, Gaithersburg, MD) on the Bio Rad
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The
following primers were used: IL-6 forward, 5’-TCCAGTTGCCTTCTTGGGAC-3’; IL-6
reverse, 5’-TCCAGTTGCCTTCTTGGGAC-3’; TNF forward, 5’AGCACAGAAAGCATCATCCGC-3’; TNF reverse, 5’TGCCACAAGCAGGAATGAGAAG- 3’; VEGF forward, 5’GAGGATGTCCTCACTCGGATG-3’; VEGF reverse, 5’GTCGTGTTTCTGGAAGTGAGCAA-3’; MMP-9 forward, 5’GCCCTGGAACTCACACGACA-3’; MMP-9 reverse, 5’TTGGAAACTCACACGCCAGAAG-3’; TGFβ-1 forward, 5’GTGTGGAGCAACATGTGGAACTCTA-3’; TGFβ-1 reverse, 5’TTGGTTCAGCCACTGCCGTA-3’; FGF-2 forward, 5’CCAACCGGTACCTTGCTATG-3’; FGF-2 reverse, 5’TATGGCCTTCTGTCCAGGTC-3’; β-actin forward, 5’GATGACGATATCGCTGCGC-3’; β-actin reverse, 5’CTCGTCACCCACATAGGAGTC-3’.
All primers were purchased from Eurofins MWG Operon (Huntsville, AL).

II.3.5 Statistical Analysis
Data are presented as mean ± SE and analyzed using GraphPad Prism 6 software
(GraphPad, La Jolla, CA). Comparisons between two groups were done using unpaired
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Student’s t test and comparisons between multiple groups were done using one-way
analysis of variance with Tukey’s post-hoc test. All p values <0.05 were deemed
significant.

II.4 RESULTS

II.4.1 Fabrication of Electrospun Scaffolds
We first sought to demonstrate the ability to create electrospun scaffolds with
varying geometries. Previous work has shown that altering polymer concentration is a
feasible approach to changing the architecture of electrospun scaffolds. Therefore we
generated electrospun scaffolds with the lowest and highest polymer concentrations
possible, using 60 mg/mL and 140 mg/mL of polydioxanone. Polymer concentrations of
polydioxanone below 60 mg/mL led to uneven dispersal at the needle tip and failed to
produce a usable scaffold. Additionally, concentrations above 140 mg/mL were too
viscous to consistently electrospun scaffolds. Figure 2.1 features electron micrographs of
electrospun polydioxanone scaffolds from 60 and 140 mg/mL polymer solutions. 60
mg/mL scaffolds featured fibers with a diameter of 400nm and pores with an
approximate diameter of 1.5μm, while 140 mg/mL scaffolds contained fibers with a
diameter of 2.4μm and pores with a diameter of 18μm. These large variations permitted
us to examine how scaffolds architecture alters mast cell inflammatory responses.
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FIGURE 2.1 Electrospun polydioxanone scaffolds Polydioxanone scaffolds of
different polymer concentrations were electrospun, yielding scaffolds of different
morphologies, as confirmed by scanning electrospun microscopy. Electron microgrpahs
were used to characterize fiber and pore diameters of the electrospun scaffolds. . *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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II.4.2 Altered Mast Cell Cytokine Production on Scaffolds of Varying Morphologies
Over the last decade, studies of macrophage responses, including our own, have
shown scaffold capacity to modulate inflammation, promote angiogenesis, and control
tissue remodeling (38, 65-67). The ethos of tissue engineering and regenerative medicine
over the last decade has largely been that if implants or therapies can elicit an M2
phenotype from macrophages, then the fate of the implant or therapy will be favorable
(68). There is certainly credibility to that outlook, since macrophages are a critical tissueresident population of innate immune cells present throughout the body. Even though
macrophages in various tissues bear different names (e.g. Kuppfer cells, Langerhans
cells, osteoclasts, and microglia), macrophages are nonetheless nearly ubiquitously
present. However, they do not exist or operate independently of other tissue-resident
innate immune cells. Therefore, there is a need to explore the role and responses of other
innate immune cells in regard to tissue engineering therapies.
Our group has shown that mast cells adhere to fibronectin-coated polydioxanone
scaffolds (69). Additionally, mast cells are not activated by the scaffold architecture
alone, allowing us to test various stimuli. In the context of tissue damage, IL-33 and LPS,
endogenous and exogenous cell injury signals respectively (23), should be abundant.
Therefore, we examined how fibronectin-coated scaffolds with varying morphologies
altered IL-33- and LPS-mediated mast cell cytokine production.
After electrospinning, 10mm diameter segments of scaffolds were coated with
fibronectin and held in place with 8mm cloning rings to help concentrate cells onto the
membrane. BMMC were seeded and 48 hours later subsequently activated with IL-33,
LPS, or neither. Supernatants were collected after 16 hours and analyzed via ELISA.
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Figure 2.2 shows that in response to IL-33 or LPS, mast cells on 140 mg/mL scaffolds
secreted less IL-6 than cells cultured on 60mg/ml membranes. This was also true of TNF
secretion but only in response to IL-33 activation. This demonstrated that altering
scaffold structure is able to suppress IL-33- and LPS-mediated inflammatory cytokine
secretion. Moreover, this effect appears to be selective, since chemokine production was
unchanged by scaffold structure (Figure 2.3). Moreover, VEGF secretion was
significantly enhanced among IL-33-stimulated BMMC on 140 mg/mL scaffolds (Figure
2.4). All together, these data demonstrate that relative to 60 mg/mL scaffolds, the 140
mg/mL scaffolds, which have larger fiber and pore diameters, reduce inflammatory
cytokines and enhance pro-angiogenic cytokines. This indicates that our group’s earlier
findings of altered macrophage phenotype on scaffolds has a parallel in the mast cell
response (38).
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FIGURE 2.2 Mast cell IL-6 and TNF production is altered on scaffolds of different
morphologies BMMC were seeded on fibronectin-coated electrospun scaffolds for 48
hours and then activated with LPS (1 μg/mL) or IL-33 (100 ng/mL). Supernatants were
collected 16 hours later and analyzed via ELISA for IL-6 and TNF. Results are presented
as mean ± SEM. Figures are 3 indpendent experiments conducted in triplicate. . *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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FIGURE 2.3 Mast cell MCP-1 and MIP-1α production is altered on scaffolds of
different morphologies BMMC were seeded on fibronectin-coated electrospun scaffolds
for 48 hours and then activated with LPS (1 μg/mL) or IL-33 (100 ng/mL). Supernatants
were collected 16 hours later and analyzed via ELISA for MCP-1 and MIP-1α. Results
are presented as mean ± SEM. Figures are 3 indpendent experiments conducted in
triplicate. . *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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FIGURE 2.4 Mast cell VEGF production is altered on scaffolds of different
morphologies BMMC were seeded on fibronectin-coated electrospun scaffolds for 48
hours and then activated with LPS (1 μg/mL) or IL-33 (100 ng/mL). Supernatants were
collected 16 hours later and analyzed via ELISA for VEGF. Results are presented as
mean ± SEM. Figures are 3 indpendent experiments conducted in triplicate. . *, p<0.05;
**, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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II.4.3 Scaffold Morphology Alters Mast Cell Cytokine mRNA Expression
While Figure 2.2 demonstrated a trend among cytokines that matched a phenotype
described in earlier work, there was a variable that needed to be addressed. The scaffolds
were coated with fibronectin, which contains a growth factor-binding domain (70). It is
possible that the changes in cytokine detection could be attributed to sequestration at the
scaffold surface via fibronectin binding. Therefore, cytokines mRNAs were measured.
BMMC were seeded on fibronectin-coated 60 and 140 mg/mL polydioxanone scaffolds.
To streamline the work, BMMC were activated only with IL-33, due to consistent
suppression of IL-33-mediated inflammatory cytokine secretion and enhancement of
VEGF. As observed at the protein level, 140 mg/mL polydioxanone scaffolds enhanced
IL-33-mediated expression of VEGF mRNA (Figure 2.5). Additionally, 140 mg/mL
scaffolds significantly enhanced IL-33-mediated production of MMP-9 mRNA. MMP-9
has been shown to play a critical role in angiogenesis, which further confirms the proangiogenic mast cell phenotype promoted by the 140 mg/mL scaffold (71).
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FIGURE 2.5 Mast cell cytokine and protease expression is altered on scaffolds of
different morphologies at the mRNA level BMMC were seeded on fibronectin-coated
electrospun scaffolds for 48 hours and then activated with IL-33 (100 ng/mL). RNA was
harvested 3 hours later and analyzed via qPCR for VEGF and MMP-9. Results are
presented as mean ± SEM. Figures are 2 indpendent experiments conducted in triplicate. .
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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II.4.4 Increased Pore Size of 60 mg/mL Polydioxanone Scaffolds
While 60 mg/mL and 140 mg/mL scaffolds elicit very different responses from
mast cells, the two scaffolds are different in two ways, fiber diameter and pore size.
Therefore these two variables need to be acknowledged and accounted for. It is feasible
to create scaffolds with the same fiber diameters but different pore sizes. We first focused
on the 60 mg/mL scaffold, attempting to generate a scaffold with the same small fiber
diameter, but with increased pore sizes.
In 2012, Michael McClure and colleagues published a method for increasing
electrospun scaffold pore size without changing fiber diameter (72). In place of the
standard solid, closed-surfaced rotating mandrel, they fabricated a hollow mandrel with
perforations throughout the surface. One end of the mandrel is connected to tubing that
forces air through the perforations, generating regions with large pore sizes. The inlet
pressure is entirely controllable, though the previous work done by McClure and
colleagues determined that the optimal inlet pressure was 50 kPa. When the inlet pressure
is at between 50 and 100 kPa, there is increased scaffold pore size and permeability.
However, as the inlet pressure exceeds 100 kPa, the pressurized air striking the closed
end of the mandrel causes a balloon-like structure to form at that end of the mandrel.
Therefore, we used 50 kPa as our inlet pressure. While the areas directly above the
perforations have larger pore sizes, the pore sizes throughout the structure are larger as
well. Therefore, we employed this method to create 60 mg/mL scaffolds with larger pore
sizes but the same fiber diameters as a 60 mg/mL scaffold electrospun onto a solid
mandrel.
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Figures 2.6A and 2.6B show electron micrographs of 60 mg/mL scaffolds
electrospun onto solid mandrel (60) and air-flow mandrels (60AF). The images illustrate
the differences in their respective morphologies, which was quantified in Figure 2.6C.
Additionally, Figure 2.6B shows images of the air-flow mandrel and a low magnification
electron micrograph of the regions with larger pore sizes. Figure 2.6C shows that the 60
mg/mL scaffold electrospun onto the air-flow mandrel contains significantly larger pore
sizes, approximately 4 μm in diameter compared to 1.5 μm in diameter for the 60 mg/mL
scaffold from the solid mandrel. However, there is no difference in fiber diameter
between the two scaffolds. Therefore, differences observed in mast cell responses to the
two scaffolds can be attributed to their different pore sizes.
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FIGURE 2.6 Increasing pore size of 60 mg/mL electrospun scaffolds. Electron
micrographs of 60 mg/mL polydioxanone scaffolds electrospun on A) a solid mandrel
and B) air-flow mandrel. B) also features an image of the air-flow mandrel (72). C) Fiber
and Pore diameter were measured using ImageJ to analyze scaffold morphology. *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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II.4.5 Altered Mast Cell Cytokine Secretion on 60 vs 60AF Scaffolds
In order to determine if increasing scaffold pore size alone alters mast cell
cytokine secretion, mast cells were seeded on 60 mg/mL scaffolds from the solid mandrel
and the air-flow mandrel. Similar to before, BMMC were seeded onto fibronectin-coated
scaffolds and activated with IL-33, LPS, or neither. 16 hours later, supernatants were
collected and analyzed via ELISA. Figure 2.7 shows that scaffolds from the air-flow
mandrel with larger pore sizes were able to significantly reduce IL-6 and TNF secretion
from BMMC activated with IL-33 or LPS, compared to the scaffolds from the solid
mandrel. This demonstrates that even between scaffolds with the same fiber diameter,
changing pore size can greatly alter inflammatory cytokine secretion.
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FIGURE 2.7 Mast cell cytokine secretion on 60 and 60AF scaffolds BMMC were
seeded on fibronectin-coated 60 and 60 AF electrospun scaffolds for 48 hours and then
activated with LPS (1 μg/mL) or IL-33 (100 ng/mL). Supernatants were collected 16
hours later and analyzed via ELISA for IL-6 and TNF. Results are presented as mean ±
SEM. Figures are 3 indpendent experiments conducted in triplicate. . *, p<0.05; **,
p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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II.4.6 Reduced Pore Size of 140 mg/mL Polydioxanone Scaffolds
To complement the air mandrel studies using 60 mg/ml membranes, we next
altered pore size on the 140 mg/ml scaffolds. We showed earlier that these membranes,
with larger diameter fibers and pores, elicit less inflammatory cytokine production from
BMMC when compared to the 60 mg/ml scaffolds. Therefore, we determined if reducing
the pore size of 140 mg/mL scaffolds enhances inflammatory cytokine secretion.
Scaffolds were compressed using a hydraulic press that provided a uniform pressure
across the scaffold. To ensure that the amount of pressure applied was consistent from
sample to sample, the arm to close the clamp on the sample was fully swung each time.
Scanning electron micrographs were used to measure pore size and fiber diameter. As
shown in Figure 2.8, there is a clear visual difference in the morphology of 140 mg/mL
polydioxanone scaffolds before (140) and after (140C) compression, but no changes in
fiber diameter. The 140 scaffold had an approximate pore diameter of 18 μm, while the
140C scaffold pores were reduced to 6 μm. Both scaffolds had a fiber diameter of
approximately 2.4 μm. Thus we selectively reduced pore size without changing fiber
diameter.
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FIGURE 2.8 Decreasing pore size of 140 mg/mL electrospun scaffolds Electron
micrographs of electrospun 140 mg/mL polydioxanone scaffolds that are either unaltered
or have been compressed to reduce pore size. Fiber and Pore diameter were measured
using ImageJ to analyze scaffold morphology. *, p<0.05; **, p<0.01; ***, p<0.001;
****, p<0.0001; NS, not significant.
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II.4.7 Mast Cell Cytokine Secretion on 140 vs 140C electrospun scaffolds
Using the scaffolds shown in Figure 2.8, we determined if reducing pore size
without changing fiber diameter could increase inflammatory cytokine secretion from
mast cells. BMMC were seeded onto 140 or 140C scaffolds and activated with IL-33,
LPS, or neither. 16 hours later supernatants were collected and analyzed via ELISA. As
shown in Figure 2.9, LPS-induced IL-6 and TNF secretion was unchanged on the 140C
scaffolds. Moreover, IL-33-induced cytokines were inconsistent. TNF production was
reduced below detectable levels when BMMC were cultured on 140C membranes – but
IL-6 production surprisingly increased. One conclusion may be that with fiber diameters
on the micron scale, pore sizes are not critical. However, that seems unlikely given
previous work demonstrating reduced M2 macrophage polarization on scaffolds with
micron fiber diamters and reduced pore size (38). An alternative explanation may be that
since the pore diameter of the140C scaffolds is approximately 6 μm, that size may be
sufficient to elicit a response from BMMC that suppresses inflammatory cytokines. That
pore diameter resembles the 60AF scaffold (4µm) that suppressed IL-33-mediated mast
cell inflammatory cytokine secretion, despite the sub-micron fiber diameters. Perhaps a
scaffold geometry with pore sizes of 6 μm is on the verge of being sufficiently different
from scaffolds with pore sizes of 18 μm to alter inflammatory cytokine secretion. Mast
cells have an approximate diameter of 10 μm, which may explain why scaffolds with
pore sizes of 6 μm vs. 18 μm might not elicit different inflammatory responses (73). Mast
cells may still be able to engage with a scaffold that has 6 μm pores as it does with a
scaffold with 18 μm pores. This will require further investigation where the pore sizes of
compressed 140 mg/mL scaffolds are further reduced to approximately 3 μm. We
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conclude that in the presence of large fibers, reducing pore size to 6 μm does not
consistently increase inflammatory cytokine secretion from mast cells.
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FIGURE 2.9 Mast cell cytokine secretion on 140 and 140C scaffolds BMMC were
seeded on fibronectin-coated 140 and 140C electrospun scaffolds for 48 hours and then
activated with LPS (1 μg/mL) or IL-33 (100 ng/mL). Supernatants were collected 16
hours later and analyzed via ELISA for IL-6 and TNF. Results are presented as mean ±
SEM. Figures are 3 indpendent experiments conducted in triplicate. . *, p<0.05; **,
p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.

46

II.5 DISCUSSION
Electrospinning offers great promise as a method for fabricating synthetic grafts
that are inexpensive, have the potential to be bioresorbable, and have off-the-shelf
availability. Additionally, the sub-micron fiber diameters of electrospun scaffolds allow it
to mimic the structure and function of the native extracellular matrix (ECM) (74).
However, one major limitation of electrospinning is the inability to finely control scaffold
porosity. Scaffold porosity is the design focus that is most vital for promoting healing,
transmural angiogenesis (i.e. capillary in-growth through the walls of the implant), and
cellular infiltration for tissue growth. Sufficient endothelialization is one major limitation
of many vascular prosthetics and can be addressed by increasing porosity throughout an
implant by facilitating transmural angiogenesis (75). Currently, clinically used synthetic
grafts undergo transanastomotic endothelialization (i.e. endothelium growth from the
adjacent vessel into graft), however, this phenomenon provides extremely limited
endothelium growth. Therefore, the solution would be to promote capillary in-growth
throughout the walls of the implant (76). Beyond endothelial growth, fibroblast migration
into the implant is important for tissue remodeling. Both of these issues can be facilitated
by increasing the porosity of the implant. The success of electrospun scaffolds has been
limited due to the inability to directly control pore size due to the tight packing of the
fibers (77). Therefore it is imperative to find ways to alter scaffold structure to improve
functionality.
Another variable that can dictate the fate of any implanted biomaterial is the
initial interaction with the immune system. If the response elicited by introduced
scaffolds from innate immune cells is inflammatory, it can lead to scaffold rejection,
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capsule formation, and failure (51). Addressing this variable was the over-arching goal of
this work. In the present study we sought to determine if changing electrospun scaffold
geometry could alter the response from innate immune cell populations. Our group has
previously published that increasing pore and fiber diameter promoted an M2
polarization of macrophages cultured on these scaffolds. While the macrophage response
to these scaffolds is important, macrophages do not respond to these materials
independently of other cells, nor do they exist in the tissue independently. Therefore it is
important to characterize the response of other innate immune cells that reside in the
peripheral tissue with macrophages. This is why we characterized the mast cell response
to electrospun scaffolds.
Since it is critical to improve the pore size of electrospun scaffolds and mitigate
the inflammatory response from the tissue resident innate immune cells, this work sought
to unite the two topics of study by examining how altering scaffold structure might
modulate the response from mast cells. We demonstrated in this chapter that scaffold
pore size could be increased in response to increasing fiber diameter, which is achieved
by increasing polymer concentration during electrospinning. However, the pitfall with
this method is losing the sub-micron fiber diameters that closely mimic the structure of
the native ECM. Therefore there was a need to maintain sub-micron fiber diameters while
increasing scaffold pore size. Previous work has shown that while scaffolds like our 60
mg/mL polydioxanone scaffold have sub-micron fiber diameters, the dense morphology
of these polymers promote inflammatory responses. Macrophages will fuse together to
form multinucleated foreign body giant cells (FBGCs) when met with a material they
cannot infiltrate nor engulf, such as an electrospun scaffold with low fiber and pore

48

diameter. In this scenario, FBGCs will begin to release highly inflammatory reactive
oxygen species in an attempt to break down the material (38). This points towards a
relationship between implant architecture and mediating inflammatory responses. So the
explicit goal is to create a scaffold with sub-micron fiber diameters that have increased
scaffold pore size. This was accomplished with the introduction of the air-flow mandrel.
While we demonstrated that the 140 mg/mL scaffold prompted BMMC to release less
inflammatory cytokines than the 60 mg/mL scaffold in response to IL-33 and LPS, the
140 mg/mL scaffold does not offer desirable fiber diameters. However, when 60 mg/mL
scaffolds were electrospun onto the air-flow mandrel and seeded with BMMC, the 60AF
scaffold promoted significantly less mast cell inflammatory cytokine production in
response to IL-33 and LPS. This demonstrates a way to make electrospun scaffolds with
fiber diameters that still mimic the native ECM, but with larger pore sizes. We also
demonstrate how the changes in scaffold pore size promote an anti-inflammatory and
pro-angiogenic phenotype. This work corroborates previous findings and helps to address
a pressing need in the field of biomaterial design.
One point worth making is that while macrophages do not require scaffolds to be
coated with an adhesion-promoting protein, mast cells do, as reported in our earlier study
(69). In this work, scaffolds were coated with fibronectin prior to mast cell seeding.
While this does not initially seem to mimic normal physiology, previous work has
demonstrated the role of plasma fibronectin on scaffold fate and the foreign body
response. When biomaterials were implanted in mice deficient in plasma fibronectin,
fibrotic capsules were thicker and more foreign body giant cells were present. This
indicates a critical role for plasma fibronectin in mitigating inflammatory responses to

49

biomaterials (78). This is by no means a reason to coat each implanted biomaterial with
fibronectin, but suggests that coating electrospun scaffolds with fibronectin may have
physiological relevance. All together, this work provides another perspective on how
biomaterials should be designed to mitigate inflammatory responses.
II.6 CONCLUSION
In this study we demonstrate that LPS- and IL-33-mediated mast cell responses to
electrospun scaffolds can be modulated with scaffold structure. When comparing the 60
mg/mL polydioxanone scaffold to the 140 mg/mL, which had larger pore and fiber
diameters, the latter elicited less inflammatory cytokine and more VEGF secretion.
Further, by increasing the pore size of the 60 mg/mL scaffold, mast cells secreted less
inflammatory cytokines. These findings provide helpful information that is necessary in
biomaterial design when considering parameters meant to mitigate inflammation. As the
importance of managing inflammation and innate immune responses to biomaterials
rises, studies such as this will provide a better understanding in how to do so.
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CHAPTER III: LACTIC ACID SUPPRESSES IL-33MEDIATED MAST CELL INFLAMMATORY
RESPONSES VIA HYPOXIA INDUCIBLE FACTOR
(HIF)-1α-DEPENDENT miR-155 SUPPRESSION
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III.1 ABSTRACT
Lactic acid (LA) is elevated in tumors, the asthmatic lung, and wound
healing, environments with elevated IL-33 and mast cell infiltration. LA is also a
degradative byproduct of poly-lactic acid breakdown (PLA). PLA is a widely used
synthetic polymer in biomaterial design. While IL-33 is a potent mast cell activator, how
LA affects IL-33-mediated mast cell function is unknown. To investigate this, mouse
bone marrow-derived mast cells (BMMC) were cultured with or without LA and
activated with IL-33. LA reduced IL-33-mediated cytokine and chemokine production,
yet enhanced VEGF. Using inhibitors for monocarboxylate transporters (MCT) or
replacing LA with sodium lactate revealed that LA effects are MCT-1- and pHdependent. LA selectively altered IL-33 signaling, suppressing TAK1, JNK, ERK, and
NFkB phosphorylation, but not p38 phosphorylation, and enhanced Akt phosphorylation.
We connected the enhancement of VEGF production and Akt phosphorylation by
showing that IL-33-mediated VEGF production requires Akt1 expression. LA effects in
other contexts have been linked to HIF-1α, which was enhanced in BMMC treated with
LA. Since HIF-1α has been shown to regulate the microRNA miR-155 in other systems,
LA effects on miR-155-5p and -3p species were measured. In fact, LA selectively
suppressed miR-155-5p in a HIF-1α-dependent manner. Moreover, overexpressing miR155-5p, but not miR-155-3p, abolished LA effects on IL-33-induced cytokine production.
These in vitro effects of reducing cytokines were consistent in vivo, since LA injected
intraperitoneally into C57BL/6 mice suppressed IL-33-induced plasma cytokine levels.
Lastly, IL-33 effects on primary human mast cells were suppressed by LA in an MCT-
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dependent manner. Our data demonstrate that LA, present in inflammatory and malignant
microenvironments, can alter mast cell behavior to suppress inflammation.

III.2 INTRODUCTION
In the previous chapter, scaffold architecture was explored as a variable
that can alter mast cell responses. Another critical factor that can alter the fate of
implanted biomaterials is the response from tissue resident innate immune cells to the
byproducts of the material. While materials degradation rates vary, all biomaterials
secrete byproducts into the local microenvironment, presenting an additional variable to
consider in designing biomaterials.
One of the most widely used synthetic polymers in biomaterials is polylactic acid
(PLA). Part of the appeal of using PLA is that it is an FDA approved polymer, has been
well studied, widely applied, and the degradative byproduct is lactic acid, which can be
metabolized and excreted as carbon dioxide and water (79, 80). PLA was first approved
by the FDA for use as a suture, but has been applied in many other ways, from use as an
orthopedic implant, drug delivery system, electrospun scaffold, and even food storage
(81). PLA is a thermoplastic polymer in the polyester class, which possess an ester
linkage in their backbone susceptible to hydrolytic degradation (82). Lactate is a chiral
molecule and comes in two forms, L-lactate and D-lactate. Unsurprisingly, PLA also
comes in two forms, poly-L-lactic acid (PLLA) and poly-D-lactic acid (PDLA). Both
PLLA and PDLA are crystalline polymers that undergo bulk erosion via hydrolysis (83).
The hydrolytic degradation of these polymers happens over the course of approximately
two years, however, it does lead to the local accumulation of lactic acid in the tissue
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microenvironment (TME) (84). Therefore, it is critical to understand how the build up of
byproducts like lactic acid can alter the fate of an implanted biomaterial, particularly how
tissue resident immune cells respond. In light of this, the next chapter will explore how
mast cells, a tissue resident immune cell, respond to lactic acid exposure.
Mast cells are sentinels of the innate immune system, guarding the body against
select bacterial and parasitic infections. However, mast cells are best known for the major
role they play in allergies and allergic asthma. The interaction of allergen with mast cellbound IgE and subsequent signaling through the IgE receptor, FcεRI, result in a signaling
cascade provoking release of early and late phase mediators (58, 85-88). The early phase
mediators, released within minutes of activation, include tryptases, chymases, histamine,
prostaglandins, leukotrienes and platelet-activating factor, whereas the late phase
mediators, released hours later, consist of cytokines and chemokines, including IL-1b,
IL-4, IL-5, IL-6, IL-10, IL-13, TNF, MIP-1α, and MCP-1. These factors yield the clinical
symptoms of immediate hypersensitivity, including the wheal-and-flare response, itching,
and vasodilation/edema. Mast cells can also promote chronic diseases such as asthma
upon repeated antigen exposure, which results in airway remodeling due to sustained
inflammation (58, 85-88).
While IgE crosslinking is the best-studied form of mast cell activation, many
stimuli elicit a mast cell response. IL-33 is a recently discovered alarmin in the IL-1
family. Produced by endothelial cells, epithelial cells, fibroblasts, mast cells, and
keratinocytes in response to damage or stress, IL-33 promotes a TH2 response (89-92).
IL-33 binding to the ST2/IL-1RacP receptor complex on mast cells results in the release
of cytokines, chemokines and lipid mediators (89, 90). IL-33 has also been shown to
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promote mast cell survival, maturation and adhesion (33, 91). While it is a poor inducer
of degranulation, IL-33 augments degranulation triggered through the IgE receptor (89,
90). IL-33 has beneficial effects in atherosclerosis, cardiac remodeling and helminth
infection (91). However, it has been linked to asthma, rheumatoid arthritis, multiple
sclerosis, Type I diabetes, and skin inflammation (90).
Inflammation causes important changes in the cellular microenvironment, which
can be beneficial if temporally and spatially controlled, but pathological when chronic. A
well-known example of chronic inflammation is the TME. Tumors are known to
preferentially undergo anaerobic glycolysis, even in the presence of sufficient oxygen,
resulting in a hypoxic microenvironment with high (40mM) lactic acid (LA)
concentrations (93-101). These unique environmental factors can alter cellular responses,
allowing tumors to escape immune surveillance (98, 101-103). There is evidence that the
TME uses LA to promote tumor-associated macrophages (TAM) to take on an M2
phenotype, which is anti-inflammatory and has reduced antigen presentation ability (94,
101). Tumor-derived LA has also been shown to inhibit dendritic cell function, resulting
in decreased proliferation and reduced antigen presentation (96). Among cytotoxic T
cells, LA decreases proliferation and inhibits their cytotoxic function (98). Other
examples of altered microenvironments that have increased lactate levels are obesity,
hypertension, and Type II diabetes, as well as tissues suffering injury, infection, or
ischemia (102-105).
Since LA is known to alter cellular responses in inflammatory environments, we
tested the effects of physiological LA concentrations on mast cell function. LA exposure
for 24 hours was sufficient to suppress IL-33-mediated cytokine secretion, effects that
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were pH- and monocarboxylate transporter-1 (MCT-1)-dependent. Suppression of IL-33induced inflammatory cytokine and chemokine secretion was accompanied by reduced
activation of several signaling intermediates. Expectedly, LA treatment enhanced HIF-1α
expression. This correlated with a decrease in pro-inflammatory miR-155-5p, which was
reversed by HIF-1α blockade. miR-155-5p overexpression abolished LA suppressive
effects, demonstrating the critical nature of the HIF-1α-miR-155 cascade. These results
provide insight into microenvironmental effects during wound healing, chronic
inflammation, and tumorigenesis.

III.3 MATERIALS AND METHODS
III.3.1 Animals
C57BL/6 male and female mice were purchased from The Jackson Laboratory (Bar
Harbor, ME) and used at a minimum of 6 weeks old, with approval from the Virginia
Commonwealth University institutional animal care and use committee (IACUC).

III.3.2 Mouse Mast Cell Cultures
BMMC were derived by harvesting bone marrow from C57BL/6 mouse femurs, followed
by culture in complete RPMI (cRPMI) 1640 medium (Invitrogen Life Technologies,
Carlsbad, CA) containing 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin, 1mM sodium pyruvate, and 1mM HEPES (all from Corning, Corning,
NY), supplemented with IL-3-containing supernatant from WEHI-3B cells and SCFcontaining supernatant from BHK-MKL cells. The final concentrations of IL-3 and SCF
were adjusted to 1.5ng/ml and 15ng/ml, respectively, as measured by ELISA. BMMC
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were used after 3 weeks of culture, at which point these primary populations were >90%
mast cells, based on staining for c-Kit and FcεRI expression. Mouse peritoneal mast cells
were obtained by collecting peritoneal lavage from C57BL/6J mice, which cultured in
cRPMI supplemented with recombinant mouse IL-3 and SCF at 10ng/mL each.
Peritoneal mast cells were used after 14 days, at which these ex vivo expanded cells were
approximately 85% mast cells, based on staining for c-Kit and FcεRI expression.

III.3.3 Cytokines and Reagents
Recombinant mouse IL-3, SCF, and IL-33, recombinant human IL-33, as well as mouse
IL-6, TNF, and MCP-1 (CCL-2) ELISA kits were purchased from BioLegend (San
Diego, CA). Mouse MIP-1α (CCL-3) and VEGF ELISA kits were purchased from
PeproTech (Rocky Hill, NJ). Mouse IL-13 ELISA kits were purchased from eBioscience
(San Diego, CA). L-(+)-lactic acid and Sodium L-lactate were purchased from SigmaAldrich (St. Louis, MO). Human IL-6, TNF, and MCP-1 ELISA kits were purchased
from BD OptEIA (BD Biosciences; Franklin Lakes, NJ).

III.3.4 Cell Culture Conditions
For IL-33 activation, BMMC (2x106 cells/mL) were cultured in 20ng/mL of IL-3 and
SCF in cRPMI. An equal volume of 25mM LA in cRPMI was added to the cell
suspension, resulting in a final cell concentration of 1x106 cells/ml, 10ng/mL of IL-3 and
SCF, and 12.5mM LA. Control conditions received cRPMI in place of LA. After 24
hours of pretreatment in LA media, cells then received 100ng/mL of IL-33 for 16 hours,
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after which supernatants were collected. pH was measured for media alone, lactic acid,
and lactate-conditioned media using the Beckman Phi 45 pH meter.

III.3.5 Intracellular Staining with Flow Cytometry
Cells were first treated with 12.5 mM LA and activated with IL-33 (100 ng/mL). 90
minutes after activation, cells were given Monensin (5 μM) for 6 hours to promote
cytokines accumulation in the Golgi complex, and incubated at 37°C. Cells were washed
twice with PBS and fixed with 4% paraformaldehyde (PFA) at room temperature for 20
minutes. Cells were then placed in a permeabilizing buffer, which consisted of 500 mL of
FACS buffer, 5 mL of HEPES, and 2.5 g of Saponin. After 20 minutes at room
temperature in permeabilizing buffer, cells were stained for cytokines, washed twice in
PBS, placed back in FACS buffer, and run on a FACSCelesta flow cytometer.

III.3.6 Western Blot Analysis
Cells were cultured at 2x106/ml and lysed in Lysis Buffer (Cell Signaling Technology,
Danvers, MA) supplemented with 1.5X ProteaseArrest (G-Biosciences, Maryland
Heights, MO). Protein concentration was determined using the Pierce BCA protein assay
kit (Thermo Scientific). Proteins were resolved by SDS-PAGE using 30 µg of total
protein per sample on 4-20% Mini-Protean TGX Gels (Bio-Rad, Hercules, CA). Transfer
was made onto nitrocellulose membranes, which were then blocked for 1 hour at room
temperature with 2% BSA in PBS. Membranes were rinsed in PBS and then incubated
overnight at 4oC in PBS-T containing 2% BSA and primary antibody diluted 1:1000.
Membranes were probed with antibodies purchased from Cell Signaling Technology
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(Danvers, MA), including: anti phospho-TAK1 (Thr-184/187, catalog no. 4508), total
TAK1 (catalog no. 5206), phospho-NFkB p65 (Ser-536, catalog no. 13346), total NFkB
p65 (catalog no. 4764), phospho-JNK (Thr-183/Tyr-185, catalog no. 9251), total JNK
(catalog no. 9258), phospho-p38 (Thr-180/Tyr-182, catalog no. 9216), total p38 (catalog
no. 9212), phospho-Akt (Ser473, catalog no. 4060), total Akt (catalog no. 4685), total
Akt1 (catalog no.2938), total Akt2 (catalog no. 2964), phospho-ERK1/2 (Thr-202/Tyr204, catalog no. 9101), total ERK1/2 (catalog no. 4695), and GAPDH (catalog no. 2118).
Membranes were washed the next day with PBS-T every 5 minutes for a total of 30
minutes, then incubated with a 1:15,000 dilution of either goat anti-rabbit DyLight800
(catalog no. 5151) or goat anti-mouse DyLight680 (catalog no. 5470) infrared-labeled
secondary antibodies (Cell Signaling Technology, Danvers, MA). Membranes were
rinsed a final time before being analyzed with an Odyssey CLx infrared scanner (Li-Cor,
Lincoln, Nebraska). Normalization was done using Image Studio 4.0 software (Li-Cor,
Lincoln, Nebraska).

III.3.7 Inhibitors
TAK1 inhibitor (5Z)-7-Oxozeanol (5 μM; Tocris Bioscience, Bristol, UK), JNK inhibitor
SP600125 (10 μM; EMD Millipore, Billerica, MA), NFκB inhibitor BAY 11-7085 (2
μM; Tocris Bioscience, Bristol, UK), Akt inhibitor Akt Inhibitor IV (EMD Millipore,
Billerica, MA), ERK inhibitor FR180204 (25 μM; Cayman Chemical, Ann Arbor, MI)
and monocarboxylate transporter (MCT) inhibitors α-cyano-4-hydroxycinnamic acid
(CHC; 5 mM; Sigma Aldrich, St. Louis, MO) and AR-C155858 (100 nM; Tocris
Bioscience, Bristol, UK), were solubilized in dimethyl sulfoxide (DMSO). Under the
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conditions used, none of these inhibitors caused significant cell death. Inhibitors were
added to culture one hour prior to activation with IL-33 (100 ng/mL). Supernatants were
collected 16 hours later, and ELISAs used to determine cytokine production.

III.3.8 mRNA and microRNA qPCR
After BMMC were treated in 12.5mM LA, total RNA was extracted with TRIzol reagent
(Life Technologies, Grand Island, NY) and later measured using the Thermo Scientific
NanoDrop™ 1000 UV–vis Spectrophotometer (Thermo Scientific, Waltham, MA)
according to the manufacturer’s recommended protocol. For RNA extraction used to
measure microRNA expression, polyadenylation was done prior to cDNA synthesis using
the qScript microRNA cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD). For
samples used to measure mRNA expression, cDNA was synthesized using the qScript
cDNA Synthesis Kit (Quanta Biosciences, Gaithersburg, MD) following the
manufacturer’s protocol. qPCR analysis was performed with Bio Rad CFX96 Touch™
Real-Time PCR Detection System (Hercules, CA) and SYBR® Green detection using a
relative Livak Method (106). Each reaction was performed according to the
manufacturer’s protocol using 10ng of sample cDNA, with the following primers: mmumiR-155-5p, 5’-UUAAUGCUAAUUGUGAUAGGGGU-3’ (cat no. MMIR-0155,
Quanta Biosciences); mmu-miR-155-3p, 5’-CUCCUACCUGUUAGCAUUAAC-3’ (cat
no. MMIR-0155*, Quanta Biosciences); HIF-1a forward, 5’TGAGGCTCACCATCAGTTAT – 3’; HIF-1a reverse, 5’TAACCCCATGTATTTGTTC-3’; MCT-1 forward, 5’GCTGGAGGTCCTATCAGCAG-3’; MCT-1 reverse, 5’-
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CGGACAGCTTTTCTCCTTTG-3’; MCT-2 forward, 5’TTACCGTATCTGGGCCTTTG-3’; MCT-2 reverse, 5’CCAAAGCAGTTTCGAAGGAG-3’; GAPDH forward, 5’GATGACATCAAGAAGGTGGTG-3’; GAPDH reverse, 5’GCTGTAGCCAAATTCGTTGTC-3’; SOCS1 forward, 5’CAGGTGGCAGCCGACAATGCGATC-3’; SOCS1 reverse, 5’CGTAGTGCTCCAGCAGCTCGAAAA-3’; SHIP-1 forward, 5’GGTGGTACGGTTTGGAGAGA-3’; SHIP-1 reverse, 5’ATGCTGAGCCTCTGTGGTCT-3’;
SNORD47, 5’GUGAUGAUUCUGCCAAAUGAUACAAAGUGAUAUCACCUUUAAACCGUUCA
UUUUAUUUCUGAGG-3’ (cat no. MM-SNORD47, Quanta Biosciences); b-Actin
forward, 5’-GATGACGATATCGCTGCGC-3’; and b-Actin reverse, 5’CTCGTCACCCACATAGGAGT-3’. Primers for microRNAs were purchased from
Quanta Biosciences (Gaithersburg, MD) and all other primers were purchased from
Eurofins MWG Operon (Huntsville, AL). Amplification conditions for microRNA
detection were set to heat-activation at 95 °C for 2 min followed by 40 cycles of
denaturation at 95 °C for 5s, annealing at 60 °C for 15s, and extension at 70 °C for 15s.
All other reactions consisted of a heat-activation step at 95 °C for 10 min followed by
40 cycles of 95 °C for 15s, 55 °C for 30s and 60 °C for 1 min. Fluorescence data were
collected during the extension step of the reaction.

III.3.9 siRNA and miR-mimic Transfection
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BMMC were transfected with 100nM HIF-1α siRNA (cat no. GS15251), SOCS1 siRNA
(cat no. GS12703), Akt1 siRNA (cat no. GS11651), Akt2 siRNA (cat no. GS11652), or
scrambled FlexiTube siRNA (cat no. 1027280) from Qiagen (Valencia, CA). miR-1555p (cat no. 470919), miR-155-3p (cat no. 471999), and negative control/mock (cat no.
479903) microRNA mimics were transfected at 50nM and purchased from Exiqon
(Woburn, MA). Transfections were done with the Amaxa Nucleofactor from Lonza
(Allendale, NJ) using program T5 in the following transfection media: Dulbecco’s
modified Eagle’s medium (DMEM), 20% FBS, and 50 mM HEPES Buffer. BMMC
were incubated in IL-3 and SCF (10ng/mL each) and used 48 hours after transfection.

III.310 Intraperitoneal Injections
C57BL/6J mice (12-16 weeks old) were first injected with 1mg/kg of ketoprofen from
Spectrum Chemical (New Brunswick, NJ) for pain relief, then 30 minutes later injected
with 4mg/kg of 4%(w/v) LA. 16 hours later, mice were injected with 1μg of recombinant
mouse IL-33 from eBioscience (San Diego, CA). Four hours later, mice were euthanized
and blood was collected via cardiac puncture and plasma prepared from collected blood.
All animal protocols were approved by the VCU Institutional Animal Care and Use
Committee.

III.3.11 Human Skin Mast Cell Culture
As approved by the Internal Review Board at the University of South Carolina, surgical
skin samples were collected from the Cooperative Human Tissue Network of the
National Cancer Institute. Skin mast cells were harvested and cultured from 5 human
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donors as previously described (107). After 6-10 weeks, mast cells were used, at which
time purity was nearly 100%, as confirmed with toluidine blue staining.

III.3.12 Statistical Analysis
Data are presented as mean ± SE and analyzed using GraphPad Prism 6 software
(GraphPad, La Jolla, CA). Comparisons between two groups were done using unpaired
Student’s t test and comparisons between multiple groups were done using one-way
analysis of variance with Tukey’s post-hoc test. All p values <0.05 were deemed
significant.

III.4 RESULTS
III.4.1Kinetics of Lactic Acid Auppressing IL-33-mediated Mast Cell Cytokine
Production
In a normal physiological state, LA is present in peripheral tissue at 1-2 mM
(108), whereas in pathological conditions LA concentrations often exceed 10 mM (101,
109). Elevated levels of LA are present in tissues where pathological conditions also
promote mast cell infiltration and IL-33 expression (90, 95, 96, 110). Therefore, we
investigated how LA alters IL-33-mediated mast cell activation by measuring the impact
on cytokine secretion. The timing and dose of LA treatment were determined by
measuring changes in IL-33-induced cytokine and chemokine production. LA exposure
reduced IL-33-mediated IL-6 secretion by approximately 50%, with maximal effects at 624 hours of pre-exposure. Adding LA simultaneously or 48 hours prior to IL-33 yielded
no inhibition (Figure 3.1A).
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FIGURE 3.1 Kinetics of Lactic acid suppressing IL-33-mediated mast cell cytokine
secretion. Mast cells were pretreated with 12.5 mM lactic acid prior to IL-33 activation.
Supernatants were collected 16 hrs after IL-33 activation. A) Time-course and B) doseresponse experiments were done to determine kinetics of lactic acid effects on BMMC
cytokine production. 24 hours and 12.5mM were the optimal conditions for lactic acid
pretreatment. Dotted line indicates 50% inhibition, used to calculate IC50. Supernatants
were analyzed by ELISA. Results are representative of three independent experiments
using 3 BMMC populations each, and expressed as mean ±SEM. *, p<0.05; **, p<0.01;
***, p<0.001; ****, p<0.0001; NS, not significant.
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Based on this time-course analysis, 24 hours of LA pre-exposure was determined
to be optimal. In order to determine the effective concentration of LA, BMMC were
treated with varying amounts prior to IL-33 activation. An IC50 between 6-12.5 mM was
observed for inhibiting IL-6 and MCP-1 secretion (Figure 3.1B). While 25 mM LA
yielded further inhibition of some cytokines, it also resulted in approximately 30% cell
death. Hence, we employed 12.5 mM LA, which elicited no changes in cell viability.

III.4.2 Lactic acid suppresses IL-33-mediated mast cell inflammatory cytokine production
We next sought to expand on the cytokines we measured and investigate if LA
alters the secretion of other cytokines and chemokines under the same conditions.
BMMC were treated with 12.5 mM of LA for 24 hours prior to IL-33 activation, after
which supernatants were collected to measure cytokines and chemokines via ELISA. The
inhibitory effect of LA was consistent among pro-inflammatory cytokines, since BMMC
pretreated with LA showed significantly decreased IL-33-mediated IL-6, TNF, MCP-1,
MIP-1α, and IL-13 production, yet increased VEGF production (Figure 3.2). This
phenotype, where there is selective control of inflammatory versus anti-inflammatory
cytokines, agrees with a recent paper describing LA effects on macrophage polarization
(101).
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FIGURE 3.2 Lactic acid suppresses IL-33-mediated inflammatory cytokine
secretion in mast cells. BMMC were treated as described in Figure 3.1, and supernatants
assessed by ELISA. Results are expressed are representative of three independent
experiments using 3 BMMC populations each, expressed as mean ±SEM. *, p<0.05; **,
p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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III.4.3 Lactic Acid Suppresses IL-33-mediated Peritoneal Mast Cell Cytokine Secretion
To determine if LA would also suppress IL-33-mediated cytokine secretion from
ex vivo derived mast cells, peritoneal mast cells were harvested from C57BL/6 mice via
peritoneal lavage and expanded for 2 weeks. Cells were then pretreated with LA and
activated with IL-33. As shown in Figure 3.3, LA significantly suppressed the IL-33induced production of IL-6, MIP-1α, and MCP-1 by peritoneal mast cells as well. These
findings demonstrate that LA can selectively suppress inflammatory cytokines from in
vitro differentiated as well as ex vivo expanded primary mast cells.
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FIGURE 3.3 Lactic acid suppresses IL-33-mediated peritoneal mast cell cytokine
secretion. Peritoneal mast cells harvested from C57BL/6 mice were treated with 12.5
mM lactic acid for 24 hours, then activated with IL-33 for 16 hours. Supernatants were
analyzed by ELISA. Results are expressed as mean ±SEM. Results are representative of
three independent experiments conducted in triplicate. *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001; NS, not significant.
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III.4.4 Intracellular staining for cytokine production
To determine whether the altered levels of cytokines and chemokines were due to
changes in production or secretion, we stained for cytokine proteins intracellularly via
flow cytometry. BMMC were treated with LA for 24 hours and activated with IL-33, as
in Figure 3.1. However, here we added monensin as a golgi antagonist to inhibit the
cytokine transport, leading to their accumulation in the golgi. Several hours after IL-33
activation, cells were fixed, permeabilized, and stained. In response to LA treatment,
Figure 3.4 shows that IL-33-mediated production of IL-1β and MIP-1α is suppressed.
These data indicate that LA suppresses cytokine production, but do not rule out
antagonistic effects on secretion.
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FIGURE 3.4 Lactic acid suppresses IL-33-mediated Intracellular accumulation of
cytokines in mast cells. BMMC were pre-treated with 12.5 mM LA for 24 hours and
then activated with 100 ng/mL of IL-33. 90 minutes after activation, 10 μM of monensin
was added as a golgi stop to promote the accumulation of cytokines. 6 hours later,
BMMC were fixed with paraformaldehyde, permeabilized with a Saponin buffer, and
stained for MIP-1α and IL-1β. Staining was measured using FACS. *, p<0.05; **,
p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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III.4.5 LA-mediated suppression of cytokines is pH-dependent
Previous papers have demonstrated that pH plays a critical role in LA effects on
cellular function. For example, LA has been shown to suppress LPS-induced TNF
secretion and delay NFkB activation in monocytes, while promoting an antiinflammatory M2 phenotype in macrophages (101, 111, 112). However, lactate, the salt
form of LA which does not lower pH, enhances LPS-mediated inflammatory responses in
macrophages (103). We noted that media pH decreased to 6.5 immediately after adding
LA, and returned to 7.2 within 6-8 hours (data not shown). To investigate the importance
of pH on LA effects in mast cells, BMMC were cultured in 12.5 mM LA or sodium
lactate for 24 hours prior to IL-33 activation. The results showed a clear difference, as
LA suppressed IL-33-mediated IL-6, TNF, IL-13, and MCP-1 production, while sodium
lactate had no effect (Figure 3.5), indicating the importance of pH on cytokine
production.
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FIGURE 3.5 LA effects are pH-dependent. BMMC were cultured in media alone, 12.5
mM lactic acid, or 12.5 mM sodium lactate for 24 hours prior to IL-33 activation. ELISA
was used to measure IL-6, TNF, IL-13, and MCP-1 in culture supernatants. Results are
representative of three independent experiments using 3 BMMC populations each, and
expressed as mean ±SEM.. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not
significant.
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III.4.6 LA-mediated cytokine suppression is MCT-1-dependent
Other work has demonstrated that cellular entry and egress of LA is controlled by
monocarboxylate transporters (MCT), a group of proteins within the solute carrier family
(SLC16). MCT-1 and -2 can transport lactate into the cell (113-115). While MCT-2
expression is largely restricted to the testis, heart, and brain, MCT-1 is widely expressed
including in hematopoietic cells (113, 116, 117). To determine if MCT-1 is important for
LA effects on mast cells, we treated BMMC with two different MCT inhibitors, α-cyano4-hydroxycinnamic acid (CHC; a pan-MCT inhibitor) and AR-C155858 (an MCT-1 & -2
inhibitor), and measured IL-33-induced cytokine production. In the presence of these
inhibitors, LA did not suppress IL-33-mediated IL-6 production (Figure 3.6A). To
determine MCT-1 and -2 expression in mast cells, RNA was harvested from BMMC and
analyzed via qPCR. Functionality of MCT-1 and -2 primers were confirmed by using
kidney tissue cDNA with these primers (data not shown). While MCT-1 transcripts were
easily detected in BMMC within 40 cycles, MCT-2 transcripts were not detectable at all
(Figure 3.6B). Thus these data demonstrate that LA effects on IL-33 activation are likely
dependent upon acid pH- and the MCT-1 carrier.
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FIGURE 3.6 LA effects are MCT-1 dependent. A) BMMC were treated with either
vehicle (DMSO) or the indicated MCT inhibitors, α-cyano-4-hydroxycinnamic acid
(CHC) or AR-C155858 for 1 hour prior to lactic acid or media treatment for 24 hours.
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III.4.7 Lactic acid selectively alters IL-33 signaling
We next sought to elucidate how LA alters IL-33 signaling. Flow cytometry
revealed a modest (approximately 17%) decrease in surface ST2 expression after 24
hours of LA treatment, which seemed unlikely to explain the inhibitory effects (data not
shown). Therefore we examined LA-mediated alterations in downstream signaling
events. BMMC were pretreated in 12.5 mM LA for 24 hours and activated with IL-33
before lysis. These lysates were then used to assess changes in TAK1, JNK, p38, NFkB
p65, Akt, and ERK phosphorylation, pathways shown to be important for IL-33-mediated
mast cell function (118). LA suppressed IL-33-induced activation of NFkB p65, JNK,
ERK, and TAK1, did not change p38 phosphorylation, and elevated Akt phosphorylation
(Figure 3.7). To determine if blocking these pathways alone is sufficient to mimic LA
effects, we treated BMMC with JNK, TAK1, ERK, or NFkB chemical inhibitors. While
the JNK inhibitor did not reproduce the same level of suppression, TAK1, NFkB, or ERK
inhibition completely abolished IL-33-mediated cytokine production, mimicking LA
effects (Figure 3.8). Thus LA inhibits multiple IL-33 signaling cascades, yielding
redundant suppression of the pro-inflammatory stimulus.
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76

IL-13

1500
1000

0
IL-33: +
Inhibitors: Vehicle

-

JNK

0
IL-33: +
Inhibitors: Vehicle

+

TAK1

IL-6

15000

****
10000
5000
0

IL-33
NFkB
0
Inhibitor (µM)

+
0

-

2

****

50

-

0

+
0

ERK
Inhibitor (µM)

25

****

100
50

ERK
Inhibitor (µM)

0

+
0

3

-

t.
on

IL-33

-3

0
C

+
25

25

-

+
2

150

IL

pg/mL
0

+
0

25

-

0

0

IL-33

0

pg/mL

5000

-

2

TNF

200

10000

+

TAK1

100

IL-6
15000

-

+

JNK

150

0
IL-33
NFkB
Inhibitor (µM)

+
2

-

TNF****

200

pg/mL

pg/mL

-

+

500

-

25

+
25
3

2000

-3

4000

****

IL

6000

pg/mL

pg/mL

*

t.

****

N.S.

on

8000

C

IL-6
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III.4.8 LA-mediated VEGF enhancement is Akt-dependent
Work in different cell populations has demonstrated a relationship between Akt
activation and VEGF expression (119, 120). Thus the enhancement of IL-33-mediated
Akt phosphorylation in the presence of LA was noteworthy, because VEGF was the only
cytokine studied whose expression was increased by LA. Therefore, we determined if the
LA-mediated enhancement of VEGF was Akt-dependent. Prior to LA treatment, BMMC
were exposed to an Akt inhibitor for 1 hour, then given LA for 24 hours, followed by IL33 activation. While in the vehicle alone condition, LA enhanced VEGF production in
response to IL-33 activation, the introduction of an Akt inhibitor abolished LA-mediated
enhancement of VEGF production (Figure 3.9). This demonstrates that the ability of LA
to enhance VEGF secretion is Akt-dependent. However, this experiment also revealed a
more complicated relationship, as IL-33 only induced VEGF secretion in the presence of
the Akt inhibitor. On balance, our results suggest that Akt represses IL-33-mediated
VEGF production, but has a positive impact on LA effects.
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FIGURE 3.9 VEGF enhancement is Akt-dependent. BMMC were pretreated for 1
hours with inhibitors (JNK: SP600125, 10 μM; TAK1: (5Z)-7-Oxozeaenol, 5 μM; NFkB:
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III.4.9 LA-mediated enhancement of VEGF is specifically Akt1-dependent
While Figure 3.9 showed that VEGF enhancement in response to LA treatment
and IL-33 activation is Akt-dependent, a risk with using chemical inhibitors is the
possibility of off-target effects. Therefore we corroborated these findings using siRNA
targeting specific Akt isoforms. Using the Jackson Phenome Database, we were able to
rule out Akt3 as a target, since myeloid cells did not express this isoform. Therefore, we
targeted Akt1 and Akt2 to determine if either is necessary for the enhancement of VEGF
in response to LA and IL-33. siRNA was transfected into BMMC using AMAXA
Nucleofector Technology from Lonza. There were four groups that received siRNA
transfection: negative control, Akt1, Akt2, and Akt1+Akt2. Cells were incubated for 48
hours after transfection before being treated with LA for 24 hours, and activated with IL33 for 16 hours. Supernatants were analyzed by ELISA. Figure 3.10 shows that while LA
enhanced VEGF secretion in cells transfected with control or Akt2-targeting siRNA, the
group transfected with siRNA against Akt1 was resistant to LA effects. Similarly, the
group with siRNAs against both Akt1 and Akt2 were not able to enhance VEGF with LA
treatment. This confirms the chemical inhibitor data from Figure 3.9, and specifically
identifies the Akt1 isoform as being required for LA to enhance VEGF secretion.
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III.4.10 LA enhances HIF-1α expression while selectively suppressing miR-155-5p
The microRNA miR-155 has recently emerged as a powerful pro-inflammatory
regulator, by virtue of its ability to target and suppress inhibitory proteins (121). Since
LA is known to promote HIF-1α production (101, 122, 123) and HIF-1α can control
miR-155 expression (124-126), we hypothesized that LA-induced HIF-1a might suppress
miR-155, yielding a net negative effect on IL-33 signaling. After 6 hours of LA
treatment, HIF-1α mRNA increased nearly 3-fold, while miR-155-5p was suppressed
>50% in BMMC. Interestingly, the miR-155-3p species was unaffected, indicating
selectivity of these effects (Figure 3.11).

82

1.5

**

3
2
1
0

Control Lactic Acid

miR-155-5p

1.0

**

0.5

0.0

Control Lactic Acid

2.0

Fold of Control
(Relative to SNORD47)

4

hif1a

Fold of Control
(Relative to SNORD47)

Fold Induction
(Relative to !-Actin)

5

miR-155-3p
N.S.

1.5

1.0

0.5

0.0

Control Lactic Acid

FIGURE 3.11 Lactic acid enhances HIF-1α and suppresses miR-155-5p BMMC were
treated with lactic acid for 6 hours, after which RNA was to measure levels of HIF-1α or
miR-155 expression. Results are expressed as mean ±SEM. HIF-1a results are from 3
independent experiments conducted in triplicate, while other data are representative of 2
independent experiments done in triplicate. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001; NS, not significant.
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III.4.11 Suppression of miR-155-5p is HIF-1α-dependent
In an effort to determine if HIF-1α negatively regulates miR-155-5p expression,
BMMC were transfected with a control or HIF-1α-targeting siRNA. After 24 hours of
incubation, cells were treated with LA for 24 hours and then RNA was extracted to
measure miR-155-5p and HIF-1α. Figure 3.12 shows that HIF-1α transfection prevented
LA-mediated miR-155-5p suppression, demonstrating that this process is HIF-1adependent. Measuring HIF-1α via qPCR confirmed knockdown. Now knowing how
miR-155-5p suppression occurs, the next step was to determine if miR-155-5p
suppression is required for LA effects on inflammatory cytokine production.
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III.4.12 miR-155-5p blockade is required for LA-mediated suppression
To test the functional importance of miR-155-5p suppression, BMMC were
transfected with miR-155-5p or miR-155-3p mimics. BMMC transfected with a miR155-3p mimic, the species of miR-155 not affected by LA, still showed suppression of
IL-33-induced cytokine production in response to LA treatment (Figure 3.13). However,
transfecting the miR-155-5p mimic eliminated LA-mediated suppression, suggesting that
miR-155-5p downregulation is critical for LA effects (Figure 3.14).
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supernatants via ELISA. Results are representative of 2 independent experiments done in
triplicate. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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III.4.13 Lactic acid suppresses SOCS1, but SOCS1 is not required for cytokine
suppression
Based on the importance of miR-155-5p on the ability of LA to suppress
inflammatory cytokine production, it became clear how critical it was to determine what
miR-155-5p was targeting. Two of the most characterized targets of miR-155 are SOCS1
and SHIP-1 (127). Therefore, we measured the expression of SOCS1 and SHIP-1 in
response to LA treatment. After BMMC were treated for 6 hours with LA, RNA was
extracted and used to measure SOCS1 and SHIP-1 expression. As shown in Figure 3.15,
LA enhanced SOCS1 mRNA expression, while there was no change in SHIP-1. To
determine if SOCS1 enhancement is required for cytokine suppression in response to LA,
SOCS1 was knocked down in BMMC using siRNA. After siRNA transfection, cells were
treated with LA for 24 hours, activated with IL-33, and supernatants were collected 16
hours later and analyzed via ELISA. Interestingly, Figure 3.15 shows that SOCS1
knockdown did not restore cytokine levels in the presence of LA. Therefore, SOCS1
enhancement is not required for suppression of IL-33-mediated inflammatory cytokines
in the presence of LA.
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FIGURE 3.15 Lactic acid suppresses SOCS1, but SOCS1 is not required for
cytokine suppression A) BMMC were treated with 12.5 mM LA for 24 hours.
Following LA treatment, RNA was harvested and analyzed via qPCR to measure
expression of key inhibitory molecules, SOCS1 and SHIP-1 at the mRNA level.
Expression was normalized to media control group. B) BMMC were transfected with 75
nM of siRNA for either SOCS-1 or negative control and incubated in IL-3 and SCF for
48 hours. BMMC were then treated with 12. 5 mM LA for 24 hours and then activated
with 100 ng/mL IL-33. Supernatants were collected 16 hours later and analyzed via
ELISA. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant.
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III.4.14 Lactic acid suppresses IL-33-mediated inflammatory responses in vivo
Thus far, we have shown that LA suppresses IL-33-mediated mast cell
inflammatory responses in vitro and ex vivo. We next broadened this to an in vivo model.
Intraperitoneal IL-33 injection elicits mast systemic cytokine production, likely from
many ST2-expressing cells (36). Mice were first injected intraperitoneally with LA, then
16 hours later injected with IL-33. IL-33 greatly elevated plasma MCP-1 and IL-13
levels, an effect that was nearly completely reversed by LA pretreatment (Figure 3.16).
Thus LA antagonizes the pro-inflammatory effects of IL-33 in vivo as well as in vitro.
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FIGURE 3.16 Lactic acid suppresses IL-33-mediated inflammation in vivo.
C57BL/6J mice were first injected subcutaneously with ketoprofen (1mg/kg in PBS), as
an analgesic. 30 minutes later, mice were injected with either lactic acid (4mg/kg in
4%(w/v) PBS) or PBS alone. 16 hours-post LA injections, mice were injected with either
PBS or IL-33. After 4 hours, mice were euthanized, blood was collected via cardiac
puncture, and plasma cytokines were measured by ELISA. Results are expressed as mean
±SEM and n=7. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
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III.4.15 Lactic acid suppresses primary human skin mast cells in an MCT-dependent
manner
In order to determine if our mouse data are consistent in human mast cells, we
assessed the effects of LA on IL-33-induced cytokine production using primary human
skin mast cells (SkMC). SkMC from 5 healthy donors were harvested and cultured in the
presence of LA for 24 hours. Because SkMC respond poorly to IL-33 alone, we measured
IL-33-mediated enhancement of IgE responses (90). LA pretreatment suppressed both
IgE-mediated cytokine production and the enhancing effects of IL-33. Furthermore, LA
effects were completely or partially reversed by the MCT inhibitor CHC (Figure 3.17).
These data suggest that LA consistently suppresses IL-33 signaling, and mediates these
effects via MCT transporters in both murine and human mast cells.
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Figure 3.17 Primary human skin mast cell mediator release is decreased by lactic
acid in an MCT-dependent manner. Primary human skin mast cells cultured from 5
donors were treated with either DMSO or an MCT inhibitor (CHC; 2.5mM), along with
media alone or 12.5 mM lactic acid for 24 hours, then activated with either IL-33, IgE-Ag
cross linking (IgE XL), or both. Supernatants were collected 16 hours later and analyzed
by ELISA. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; N.S., not significant.
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III.5 DISCUSSION
PLA is among the most widely used synthetic polymers in biomedical research and
in clinical applications (82). In order to better understand how degradative byproducts of
scaffolds can alter innate immune responses, treating mast cells with lactic acid was a
logical choice. Most of the work to date with respect to polymer degradation has assessed
how degradation alters mechanical integrity and capacity for tissue integration (128). There
are certainly other feasible options when considering degradative byproducts, but since LA
plays a major role in many metabolic and pathological conditions, we chose it as our focus.
LA is a metabolic byproduct of anaerobic glycolysis and is known to be increased
in a variety of pathological states including cancer, obesity, type II diabetes and wound
healing (102-105). LA concentrations, which are 1-2mM in plasma at rest, can reach 20mM
during acute exercise and 40mM at tumor sites (101, 108). While LA has been shown to
inhibit cytotoxic T cell-mediated killing, promote M2 macrophage differentiation, and
prevent dendritic cell antigen presentation, its effects on mast cell function have not been
investigated (96-98, 101). Mast cells are known to participate in allergic disease, parasitic
infection, and resistance to bacteria. They have less-defined roles in cancer and wound
healing, but are known to participate in both (58, 86-88, 129-132). Our data indicate that
LA alters inflammatory cytokine production in mast cells stimulated with IL-33, a cytokine
elevated in many pathological conditions. In the context of cancer, this could promote
tumor escape from immune surveillance, an effect tumor-derived LA has been argued to
have on tumor-associated macrophages (101). In wound healing, LA may prevent a
destructive chronic inflammatory response, but might also reduce pathogen clearance.
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BMMC exhibited decreased inflammatory cytokine production when exposed to
LA prior to IL-33 activation. Similar to reports on other cell types, the inhibitory effects
of LA in our assays were tightly linked to acidity (97). While sodium lactate increases
NFkB signaling and transcription in macrophages stimulated with LPS (103, 133), LA
decreases LPS-mediated signaling in macrophages (111, 112). Sodium lactate is the salt of
LA, with the deprotonated carboxyl group linked to sodium via an ionic bond. Our results
show that without the decrease in pH, IL-33-induced cytokine and chemokine production
was unaltered. Additionally, we demonstrated that the MCT-1 transporter is critical for
LA-mediated suppression. Others have shown that MCT-1 employs proton co-transport
with lactate (134), suggesting an explanation for the importance of acidity in our assays.
Interestingly, MCT-1 was recently shown to require a chaperone protein, CD147, for its
function (114). This warrants further investigation of mast cell CD147 expression and how
this protein contributes to LA effects.
LA has been shown to suppress TLR4-mediated signaling and cytokine production
(111, 112). IL-33 signaling is still being unraveled, but shares common molecular pathways
with TLRs. IL-33 activates the MAP3K TAK1 as an apical kinase, with resulting
downstream activation of MAP kinases, NFkB, and AP-1 in mast cells (30). Our data show
that while p38 phosphorylation is not affected, TAK1, NFkB p65, ERK and JNK
phosphorylation were significantly diminished, and this correlated with decreased cytokine
production. Chemical inhibitors of TAK1, ERK, or NFkB each mimicked LA effects on
IL-33 signaling, while JNK inhibition had no effect. Whether LA effects on multiple
signaling proteins are simply due to apical TAK1 blockade yielding multiple downstream
consequences, and how LA inhibits phosphorylation are issues that require further study.
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In response to LA treatment, HIF-1α expression was elevated in mast cells, as
predicted by previous studies (101, 122, 123). A known molecule targeted by HIF-1α in
other systems is miR-155, which is pro-inflammatory in many lineages (125). Studies show
that miR-155 possesses a hypoxia response element in its promoter region, further
connecting HIF-1α and miR-155 (135). We demonstrated that LA specifically suppresses
miR-155-5p, while leaving miR-155-3p unaltered. This selectivity appears consequential,
since miR-155-5p but not -3p overexpression reversed LA effects. Despite originating from
the same transcribed pri-miRNA, it is not unusual for 5p and 3p strands from the same primiRNA to be expressed differently in mature form in response to different stimuli. By
nature of being complimentary to one another, 3p and 5p strands can have very different
targets, eliciting effects with negative or positive feedback on the degradation of these
strands (136-138). Additionally, HIF-1α silencing restored miR-155-5p levels, indicating
that in mast cells, HIF-1α negatively regulates miR-155-5p expression. This is another
example of lineage-restricted effects, since HIF-1α induces miR-155 in populations such
as epithelial cells (135). Clearly our understanding of hypoxia and tissue acidity will need
to account for variations in lineage, allowing for nuanced effects.
The functional relevance of these findings is supported by consistent effects in vivo
and on primary human mast cells. Several features of these experiments warrant further
discussion and investigation. First, a recent paper showed that reduced pH enhances IgEmediated mouse mast cell cytokine production (139). We incidentally noted the opposite
while stimulating human mast cells with IgE (Figure 7). The differences between these
studies could be due to the acids employed, assay parameters, or species variation. Kamide
et al. did not specify the acid they employed. A strong acid might have different effects
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than LA (pKa=3.86) and may not be transported by MCT-1. The previous study also
employed a 3-hour incubation, whereas we cultured for 24 hours. However, our IL-33
studies showed no enhancing effects on inflammatory cytokines at time points between 048 hours. More work should be done to examine the effect of LA on IgE-signaling. It is
also important to state that our in vivo assay did not limit LA effects to mast cells, though
mast cells are activated by systemic IL-33 (36). A variety of cytokine-producing cells
respond to IL-33. This list continues to grow and currently includes mast cells, basophils,
eosinophils, ILC2, some Th2 cells, and macrophages (32, 140-143). Therefore our results
demonstrate that LA can antagonize IL-33-induced systemic cytokine production in vivo,
but do not restrict these effects to a specific lineage. While it is striking to find nearly
complete suppression of cytokines in vivo, further study is needed to reveal how LA acts
on various lineages.
In conclusion, LA is able to suppress inflammatory responses among IL-33activated mast cells in a pH- and MCT-1-dependent manner. This suppression requires a
HIF-1α-dependent blockade of miR-155-5p. LA’s ability to suppress IL-33-mediated
inflammatory responses was reproduced in vivo and in human mast cells. These data
provide fundamental insight into how tissue microenvironments, especially in pathological
conditions, can greatly alter mast cell responses. Given our expanding comprehension of
myriad activities played by IL-33 and mast cells, understanding and intervening in these
signaling cascades is likely to be clinically important.

III.6 CONCLUSION
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In this study we demonstrated that LA is able to suppress IL-33-mediated
inflammatory cytokine secretion while enhancing VEGF secretion. The suppressive
effects of LA on IL-33-mediated inflammatory cytokine secretion were also true of ex
vivo-derived peritoneal mast cells. LA not only suppressed cytokine secretion but also
production, as determined by intracellular staining for cytokines. As illustrated in Figure
3.18, LA effects were pH- and MCT-1-dependent, based on the use of sodium lactate and
an MCT-1/2 inhibitor. LA also significantly reduced IL-33-mediated TAK1, p65, ERK,
and JNK phosphorylation, while leaving p38 phosphorylation unchanged. Interestingly,
Akt phosphorylation was enhanced in the presence of LA, which corresponded to the
increase in VEGF. In the presence of an Akt inhibitor, LA was no longer able to enhance
VEGF production. To further identify the mechanism of VEGF enhancement, siRNAs
were used that specifically knocked down the expression of the different isoforms of Akt,
which showed that VEGF enhancement in response to LA and IL-33 was Akt1dependent. LA treatment enhanced HIF-1α mRNA expression, which negatively
regulated miR-155-5p, an activity required for LA effects. In order to determine what
miR-155-5p targets are responsible for LA-mediated suppressive effects, we measured
SOCS1 and SHIP-1 expression. While SHIP-1 expression was unchanged in response to
LA treatment, SOCS1 was elevated. However, when SOCS1 expression was knocked
down by siRNA, there were no changes in cytokine production, indicating that SOCS-1
may not be required for LA-mediated suppression. When injected in vivo with IL-33, LA
suppressed MCP-1 and IL-13 in the systemic circulation. Lastly, when human SkMC
were treated with LA, IL-33 enhancement of IgE crosslinking was abolished in the
presence of LA, and this suppression was shown to be MCT-dependent. This work
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demonstrates the potential of PLA-based materials to alter mast cell behavior in the TME,
suppressing inflammatory actviities while promoting angiogenic functions. These data
inform our use of PLA scaffolds and offer new insight into how LA may serve as a
feeback regulator of inflammatory resposnes in which LA is elevated.
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FIGURE 3.18 Model of LA effects on IL-33 activation This model illustrates the
mechanism by which LA alters IL-33-mediated mast cell activation.
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CHAPTER IV: LACTIC ACID SUPPRESSES IgEMEDIATED INFLAMMATORY RESPONSES YET
PROMOTES MAST CELL-MEDIATED
ANGIOGENESIS
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II.1 ABSTRACT
IgE crosslinking is a powerful means of activating mast cells and potentiating
inflammation and angiogenesis in the local tissue microenvironment. The degradation of
PLA-based biomaterials introduces lactic acid into the local tissue, potentially altering
IgE-mediated mast cell responses. Therefore, in order to better understand how these
degradative byproducts can alter mast cell-mediated inflammation and angiogenesis,
BMMC were treated with LA prior to IgE crosslinking. LA enhanced IgE-mediated
cytokines and chemokines from BMMC, including VEGF. Conditioned supernatants
from IgE crosslinked BMMC in the presence of LA promoted robust tube formation of
endothelial cells, confirming the enhancement of angiogenic mediators in response to
LA. Interestingly, IgE-mediated cytokine production from human and mouse ex vivoderived mast cells were suppressed in the presence of LA. These mast cells being more
physiologically relevant, were used throughout the rest of the work. PMCs pre-treated
with LA secreted less inflammatory cytokines in response to IgE crosslinking but
enhanced VEGF secretion. Similarly, skin mast cells from human donors secreted less
IgE-mediated TNF and MCP-1 in the presence of LA. Using PMCs, the suppression of
cytokines in response to LA was shown to be pH- and MCT-1-dependent. Additionally,
LA treatment reduced the phosphorylation of Syk, Btk, and ERK, key signaling
molecules in the IgE pathway. Lastly, LA injected into mice undergoing passive systemic
anaphylaxis reduced the temperature drop, indicating those mice underwent less severe
anaphylaxis. All together, this demonstrates that LA suppresses IgE-mediated from ex
vivo mast cells and mast cell responses in vivo.

102

II.2 INTRODUCTION
While mast cells are responsive to a variety of stimuli, the most well characterized
means of activation is by IgE-antigen crosslinking. Mast cells express the high affinity
IgE receptor, FcεRI, which binds with an approximate affinity of KA = 1010 M-1 (144). In
mast cells, FcεRI has a tetrameric structure that consists of an IgE-binding α-chain, a
signal-amplifying β-chain, and two disulfinde-linked γ-chains critical for signaling. Both
the β-chain and γ-chains bear an immunoreceptor tyrosine-based activation motif
(ITAM) that propagates signal transduction FcεRI crosslinking (145).
After FcεRI aggregation, the beta chain-associated Src kinase Lyn phorphorylates
ITAMs on their tyrosine residues and promotes the further association of Lyn as well as
Fyn, another Src-family kinase, on the β-chain and Syk on the γ-chains. After Syk docks
at the SH2 domain of the activated γ-chain ITAM, activated Syk activates the adaptor
protein linker for activation of T cells (LAT). LAT activation promotes the assembly of a
multimolecular protein complex around LAT, that includes GRB2, SLP76, PLCγ, and
GADS. This protein complex leads to downstream activation of MAPKs critical for
cytokine production. In addition to LAT activation, another important substrate of Syk is
PI3K, which promotes the phosphorylation of PIP2 to PIP3 and subsequent activation of
several kinases, including Akt and BTK. Collectively these lead to the activation of
transcription factors, including NFkB, AP-1, and Stat5 (145-148), which promote
cytokine synthesis and secretion. Additionally, these kinases drive calcium-dependent
mast cell degranulation. Figure 4.1 features an illustration of IgE signaling summarizing
these proceses. Interestingly, while Lyn serves as an early mediator in the initial wave of
IgE signal transduction, it also supports negative feedback regulation of IgE signaling.
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Lyn tyrosine phosphorylates a non-canonical beta chain ITAM that promotes recruitment
of the phosphatases SHP-1 and SHIP-1 (149, 150). Lyn also phosphorylates C-terminal
Src kinase binding protein (CBP), which leads to antagonism of Src kinase activity.
These seemingly conflicting events demonstrate the nuanced nature of IgE signaling in
mast cells.
Mast cell activation via IgE crosslinking consists of early and late phase
responses. The early phase consisting of rapid mast cell degranulation, which introduces
a myriad of pre-formed mediators, including histamine, proteases, arachidonic acid
metabolites, proteoglycans, and some cytokines (151). This is rapidly followed by
release of inflammatory lipids, including arachidonic acid metabolites and sphingosine-1phosphate. The late phase response consists of de novo cytokine and chemokine
synthesis, which can dictate the responses of other cell populations (36, 151). These
responses are collectively inflammatory, but anti-inflammatory and pro-angiogenic
activities also occur, including synthesis and activation of latent TGFb-1, and
angiogenesis induced by VEGF, tryptase, and chymase (42-45). While most work
exploring IgE activation is in the context of allergies, mature mast cells are present in all
tissues except blood, mostly at perivascular locations. Hence IgE-mediated mast cell
responses offer a unique opportunity to modulate the FceRI signaling to alter tissue
remodeling and blood vessel growth (43, 47, 152).
In evaluating how the degradative byproducts of polylactic acid-based
biomaterials can alter mast cell responses, and given the potency of IgE crosslinking in
activating mast cells, as well as the potential to modulate inflammation and angiogenesis,
it would be a natural extension of this work to explore how LA alters IgE-mediated
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responses of mast cells. Therefore, variously sourced mast cells underwent activation via
IgE crosslinking in the presence or absence of LA to determine how this alters IgEmediated activation.
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FIGURE 4.1 Mast cell IgE signaling pathway (153) IgE-Ag crosslinking promotes the
aggregation of FcεRI and activation of various downstream signaling mediators. These
signaling events are mediated by tyrosine phosphorylation of ITAMs by Lyn on the βchain, which recruits more Lyn as well as Fyn on the β-chain ITAMs and Syk docking to
ITAMs on the γ-chains. From there, various mediators are activated that lead to the
immediate release of pre-formed mediators, in addition to promoting the de novo
synthesis of cytokines and chemokines.
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IV.3 MATERIALS AND METOHDS
IV.3.1 Animals
C57BL/6J male and female mice were purchased from The Jackson Laboratory (Bar
Harbor, ME), bred in the VCU animal care facility, and used at a minimum of 6 weeks
old, with approval from the Virginia Commonwealth University institutional animal care
and use committee (IACUC).

IV.3.2 Mouse Mast Cell Cultures
BMMC were derived by harvesting bone marrow from C57BL/6 mouse femurs, followed
by culture in complete RPMI (cRPMI) 1640 medium (Invitrogen Life Technologies,
Carlsbad, CA) containing 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin, 1mM sodium pyruvate, and 1mM HEPES (all from Corning, Corning,
NY), supplemented with IL-3-containing supernatant from WEHI-3B cells and SCFcontaining supernatant from BHK-MKL cells. The final concentrations of IL-3 and SCF
were adjusted to 1.5ng/ml and 15ng/ml, respectively, as measured by ELISA. BMMC
were used after 3 weeks of culture, at which point these primary populations were >90%
mast cells, based on staining for c-Kit and FcεRI expression. Mouse peritoneal mast cells
were obtained by collecting peritoneal lavage from C57BL/6 mice, which cultured in
cRPMI supplemented with recombinant mouse IL-3 and SCF at 10ng/mL each.
Peritoneal mast cells were used after 14 days, at which these ex vivo expanded cells were
approximately 85% mast cells, based on staining for c-Kit and FcεRI expression.

IV.3.3 Cytokines and Reagents
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Recombinant mouse IL-3 and SCF, as well as mouse IL-6, TNF, and MCP-1 (CCL-2)
ELISA kits were purchased from BioLegend (San Diego, CA). Mouse MIP-1α (CCL-3)
and VEGF ELISA kits were purchased from PeproTech (Rocky Hill, NJ). Mouse IL-13
ELISA kits were purchased from eBioscience (San Diego, CA). L-(+)-lactic acid and
Sodium L-lactate were purchased from Sigma-Aldrich (St. Louis, MO). Human TNF and
MCP-1 ELISA kits were purchased from BD OptEIA (BD Biosciences; Franklin Lakes,
NJ).

IV.3.4 Cell Culture Conditions
For IgE crosslinking, BMMC and PMC were incubated with 500 ng/mL of anti-DNP IgE
overnight. BMMC and PMC were then washed and were cultured (at 2x106 cells/mL) in
20ng/mL of IL-3 and SCF in cRPMI. An equal volume of 25mM LA in cRPMI was
added to the cell suspension, resulting in a final cell concentration of 1x106 cells/ml,
10ng/mL of IL-3 and SCF, and 12.5mM LA. Control conditions received cRPMI in place
of LA. After 24 hours of pretreatment in LA media, cells then received 50ng/mL of DNPHSA for 16 hours, after which supernatants were collected. pH was measured for media
alone, lactic acid, and lactate-conditioned media using the Beckman Phi 45 pH meter.

IV.3.5 Degranulation Assay
Mast cells were first given IgE (500 ng/mL) overnight and then treated with 12.5 mM LA
for 24 hours. During that 24 hour treatment with LA, the last 4 hours were done in the
absence of IL-3 and SCF to starve the mast cells prior to activation. Then mast cells were
activated by crosslinking IgE with DNP. 10 minutes after DNP is given, cells were
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washed twice with PBS and stained for degranulation using two antibodies, PE antiCD63 and APC anti-CD107a (BioLegend, San Diego, CA). Cells were washed twice
with PBS, resuspended in FACS buffer, and analyzed via FACS.

IV.3.6 In Vitro Angiogenesis Assay
Angiogenesis was measured using the Angiogenesis Starter Kit from ThermoFisher
Scientific (catalog no. A1460901, Waltham, MA). The assay entailed first culturing
human umbilical vein endothelial cells (HUVECs) in T175 flasks in M200 media
supplemented with Gibco Large Vessel Endothelial Supplement. When HUVECs reached
approximately 80% confluency, media was removed and trypsin was added to remove
cells from the flasks. Concurrently, 48-well plates were coated with Geltrex Basement
Membrane Matrix, which was allowed to polymerize at 37°C for 1 hour. After matrix
polymerization, HUVECs were seeded on top and allowed to migrate into the matrix.
Next, conditioned media was added on top of the matrix to promote endothelial tube
formation. 16 hours after conditioned media was added, images were captured of
endothelial tube networks. Quantification was done by doing a blinded count of the
number of tubes present in each field of view. A tube was characterized as a connection
between two different nodes of cells.

IV.3.7 Human Skin Mast Cell Culture
As approved by the Internal Review Board at the University of South Carolina, surgical
skin samples were collected from the Cooperative Human Tissue Network of the
National Cancer Institute. Skin mast cells (SkMC) were harvested and cultured from 5
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human donors as previously described (107). After 6-10 weeks, mast cells were used at
which time purity was nearly 100%, as confirmed with toluidine blue staining.

IV.3.8 Surface Staining with Flow Cytometry
BMMC were given IgE (500 ng/mL) overnight and then treated with 12.5 mM LA for 24
hours. Following LA treatment, BMMC were stained with a PE-anti IgE antibody to
determine if LA exposure stripped IgE off the surface of mast cells. Additionally, some
BMMC were not given IgE but incubated with LA and stained with a APC-anti-FcεRIα
antibody to determine if treatment altered expression of the IgE receptor FcεRI. Cells
were run and analyzed on the FACSCelesta.

IV.3.9 PhosFlow
BMMC were given IgE (500 ng/mL) overnight and then treated with 12.5 mM LA for 24
hours. During the last 4 hours of LA treatment, cells were starved from IL-3 and SCF to
remove any phosphorylation signals in response to those growth factors. Antigen was
given to induce activation and 10 minutes later, cells were fixed by incubating in 1.6%
paraformaldehyde. For permeabilization, cells were washed and then slowly added to icecold methanol solution while vortexing. Cells were then washed and stained with APC
labeled antibodies against pERK1/2, pSyk, and pBtk. Cells were then run and analyzed
on the FACSCelesta

IV.3.10 Passive Systemic Anaphylaxis
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Age-matched C57BL/6 mice (12 week old mice) first received subcutaneous injections of
1mg/kg ketoprofen from Spectrum Chemical (New Brunswick, NJ) and then 30 minutes
later intraperitoneal injections of 4mg/kg of 4% (w/v) LA. 24 hours later, all mice were
injected intraperitoneally with anti-DNP IgE (50 μg) and 16 hours later given
intraperitoneal injections of DNP (100 μg) to induce anaphylaxis. For histamine-induced
anaphylaxis, mice were given the same ketoprofen and LA injections and were given an
intraperitoneal injection of 8 mg of histamine 24 hours after the LA injection. The core
body temperature of each mouse was measured using a rectal thermometer probe
(Physitemp Instruments). Mice were then euthanized via CO2 asphyxiation and blood was
collected by cardiac puncture and centrifuged to isolate plasma.

III.3.12 Statistical Analysis
Data are presented as mean ± SE and analyzed using GraphPad Prism 6 software
(GraphPad, La Jolla, CA). Comparisons between two groups were done using unpaired
Student’s t test and comparisons between multiple groups were done using one-way
analysis of variance with Tukey’s post-hoc test. All p values <0.05 were deemed
significant.

IV.4 RESULTS
IV.4.1 Kinetics of LA enhancement of IgE-mediated cytokine secretion
In order to determine LA on IgE-mediated cytokine secretion, time-course and
concentration-response experiments were performed. First, BMMC were sensitized with
IgE overnight, then treated with various concentraton of LA for 24 hours. DNP-HSA was

111

then given to cross-link IgE, and 16 hours later supernatants were collected and analyzed
via ELISA. Figure 4.2A shows that in response to increasing doses of LA, IL-6 and
MCP-1 secretion was enhanced. At 25mM, cytokine production was no longer enhanced,
which corresponded to a decrease in cell viability (data not shown). Therefore, for the
remainder of this work LA was used at 12.5mM. To determine the optimal duration of
pre-exposure with LA, BMMC were incubated with IgE overnight and then given
12.5mM LA for periods of time ranging from 48 hours to 0 hours (i.e. simultaneously
with DNP-HSA). DNP-HSA was then added, and 16 hours later supernatants were
collected and analyzed via ELISA. Figure 4.2B shows that after 12 hours of LA
treatment, IgE-mediated secretion of IL-6 was enhanced, as well as after 24 and 48 hours.
At the 48-hour mark, cell viability began to decrease, which led us to select 24 hours as
the optimal duration for LA pre-exposure.
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FIGURE 4.2 Kinetics of LA enhancement of IgE-mediated cytokine secretion A)
BMMC were pretreated with lactic acid prior to IgE-Ag crosslinking. Supernatants were
collected 16 hrs after activation. A) Dose-response and B) time-course experiments were
done to determine kinetics of lactic acid effects on BMMC cytokine production. 24 hours
and 12.5mM were the optimal conditions for lactic acid pretreatment. Supernatants were
analyzed by ELISA. Results are representative of three independent experiments using 3
BMMC populations each, and expressed as mean ±SEM. *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001; NS, not significant.
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IV.4.2 Lactic acid enhances IgE-mediated cytokine production from BMMC
While Figure 4.2 displayed changes in IL-6 and MCP-1 secretion in response to
LA, it is important to determine if other cytokines and chemokines change accordingly
with LA treatment. BMMC were given IgE overnight and then treated with LA for 24
hours, followed with IgE crosslinking with DNP-HSA. 16 hours later supernatants were
collected and analyzed via ELISA. Figure 4.3 shows that the inflammatory cytokines IL6 and TNF, as well as the chemokines MCP-1 and MIP-1α were elevated in response to
LA. IL-13 secretion, a classic marker of IgE-mediated inflammation, was also increased
in response to LA. Interestingly, the anti-inflammatory and pro-angiogenic growth factor
VEGF was induced in response to LA. In conclusion, a panel of IgE-mediated
inflammatory cytokines and chemokines were elevated in response to LA, as well as the
angiogenic cytokine VEGF.
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FIGURE 4.3 LA enhances IgE-mediated cytokine production BMMC were pretreated
with 12.5 mM lactic acid prior to IgE-Ag crosslinking. Supernatants were collected 16
hrs after activation. Supernatants were analyzed by ELISA. Various cytokines and
chemokines were measured. Results are representative of three independent experiments
using 3 BMMC populations each, and expressed as mean ±SEM. *, p<0.05; **, p<0.01;
***, p<0.001; ****, p<0.0001; NS, not significant.

115

IV.4.3 Lactic acid does not affect IgE-mediated BMMC degranulation
A critical response to IgE crosslinking in mast cell biology is degranulation,
which involves the rapid release of pre-formed mediators, such as histamine, proteases,
arachidonic acid metabolites, and some cytokines (154). As the preformed granules move
to the cell membrane to release their contents during degranulation, unique cell surface
markers arise that can be used to measure degranulation via flow cytometry. Two such
surface markers are CD63 and CD107a (155, 156). Therefore to determine if LA alters
IgE-mediated degranulation, surface expression of CD63 and CD107a were measured.
After overnight incubation with IgE, BMMC were treated with LA for 24 hours, then
activated with DNP-HSA. Because degranulation is a rapid response, 15 minutes after
crosslinking cells were washed and stained for CD63 and CD107a. Figure 4.4 shows that
CD63 and CD107a surface expression increases with IgE crosslinking, and that LA does
not change the expression of those markers. Therefore LA does not alter appear to alter
IgE-mediated degranulation.
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FIGURE 4.4 LA does not alter IgE-mediated degranulation BMMC were pretreated
with 12.5 mM lactic acid prior to IgE-Ag crosslinking. 10 minutes after crosslinking,
cells were washed, stained for CD63 and CD107a, washed, and analyzed via FACS.
Results are representative of three independent experiments using 3 BMMC populations
each, and expressed as mean ±SEM. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001; NS, not significant.
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IV.4.4 LA enhances IgE-mediated angiogenesis
To determine if the increase in VEGF production is indicative of mast cell
angiogenic activity, supernatants from BMMC exposed to LA and IgE crosslinking were
used in an in vitro angiogenesis assay. Conditioned supernatants from BMMC were
added to the HUVEC cultures. 16 hours after conditioned supernatants were added,
images were taken of any tube networks that formed. Analysis entailed counting the
number of tubes formed between different nodes of HUVECs. As shown in Figure 4.5,
the media alone and LA alone groups were not different, as well as the IgE crosslinked
group. However, the supernatants from BMMC treated with LA and IgE crosslinked
promoted robust tube formation among HUVECs in Matrigel. Therefore, LA was able to
enhance IgE-mediated angiogenesis.
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FIGURE 4.5 LA enhances IgE-mediated angiogenesis HUVEC were seeded into a
Geltrex matrix and then exposed to conditioned supernatants from IgE-Ag crosslinked
BMMC pre-treated with LA. 16 hours following supernatant treatment, images were
captured of capillary tube network formation. Using ImageJ, images were analyzed by
quantifying tube formation by counting tubes between nodes of cells. Results are one
experiment conducted in triplicate and expressed as mean ±SEM. *, p<0.05; **, p<0.01;
***, p<0.001; ****, p<0.0001; NS, not significant.
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IV.4.5 LA suppresses IgE-mediated cytokine production from peritoneal mast cells
To determine if LA can also alter IgE responses from ex vivo derived mast cells,
murine peritoneal mast cells (PMC) were treated with LA. PMC were given IgE
overnight, then treated with LA at 12.5 mM for 24 hours, and activated with DNP-HSA.
16 hours later, supernatants were collected and analyzed via ELISA. Surprisingly, Figure
4.6 shows that in response to LA, IgE-mediated inflammatory cytokine secretion from
PMC is suppressed. This contradicts the previous findings with BMMC, where LA
enhanced inflammatory cytokines secretion. However, one consistent aspect of the
responses from BMMC and PMC is that LA enhanced IgE-mediated VEGF secretion.
There appears to be a consistent angiogenic phenotype developed in response to LA
treatment. PMC are ex vivo-derived cells and not differentiated in vitro, which makes
them more physiologically relevant. To further this work, we next studied human mast
cells.

120

IL-6
***

10000
***
5000

1500

pg/mL

pg/mL

15000

0

Media -

0

LA - Media XL LA XL

**

Media -

800

LA - Media XL LA XL

VEGF

400

1000

*

300

600

**

400

pg/mL

pg/mL

1000
500

MCP-1

200
100

200
0

TNF

2000

Media -

0

LA - Media XL LA XL

Media

LA

Media XL LA XL

FIGURE 4.6. LA suppresses IgE-mediated cytokine production from peritoneal
mast cells Peritoneal mast cells (PMC) were harvested from C57BL/6 mice and
expanded in vitro for 2 weeks. PMC were then given IgE overnight, treated with 12.5
mM for 24 hours, and then activated via IgE-Ag crosslinking. 16 hours later, supernatnats
were collected and analyzed via ELISA. Results are three experiments conducted in
triplicate and expressed as mean ±SEM. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001; NS, not significant.
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IV.4.6 LA suppresses IgE-mediated cytokine production from human skin mast cells
SkMC from human donors, which mature in vivo and are expanded ex vivo, are
conceivably one of the most physiologically relevant sources for mast cells. This work
was done in collaboration with Carole Oskeritzian at the University of South Carolina. As
before, SkMC were sensitized with IgE overnight, treated with 12.5 mM LA for 24 hours,
then activated with antigen. 16 hours later, supernatants were collected and analyzed via
ELISA. As shown in Figure 4.7, LA treatment dramatically reduced IgE-mediated
cytokine production, confirming the PMC findings in Figure 4.7. This consistency
prompted us to continue our studies using PMC.
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FIGURE 4.7 LA suppresses IgE-mediated cytokine production from human skin
mast cells Primary human skin mast cells cultured from 5 donors were treated with either
media alone or 12.5 mM lactic acid for 24 hours, then activated with IgE-Ag cross
linking (IgE XL). Supernatants were collected 16 hours later and analyzed by ELISA. *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; N.S., not significant.
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IV.4.7 LA does not strip IgE from the cell surface or alter FcεRIα levels
To better understand how LA suppresses IgE-mediated cytokine production in
PMCs, surface expression and occupancy of the high-affinity IgE receptor, FcεRI, was
measured via flow cytometry. Since acid pH has been used to strip IgE from FceRI (157),
we also determined if LA treatment affected IgE receptor occupancy. After incubating
cells overnight with IgE, then 12.5 mM LA for 24 hours, cells were stained for surfacebound IgE and analyzed via flow cytometry. Figure 4.8A shows that LA treatment does
not change FcεRI surface expression. Additionally, Figure 4.8B demonstrates that LA
treatment does not change the levels of IgE present on the cell surface. In conclusion, the
ability of LA to alter IgE-mediated responses is not due to changes in FcεRI surface
receptor expression or occupancy.
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FIGURE 4.8 LA does not strip IgE from the surface or alter FcεRIα levels A) PMC
were treated with 12.5 mM LA for 24 hours and then stained for FcεRIα to examine any
changes in surface expression. B) PMC were given IgE overnight, and then treated with
12.5 mM for 24 hours. Cells were then stained for surface-bound IgE to determine if LA
strips off IgE from the surface of mast cells. Results are three experiments conducted in
triplicate and expressed as mean ±SEM.*, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001; N.S., not significant.
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IV.4.8 LA suppress IgE-mediated cytokine production in a pH- and MCT-1-dependent
manner
In the previous chapter, we showed that LA suppresses IL-33-induced cytokine
production in a pH- and MCT-1-dependent manner (158). We therefore determined if
similar mechanism explains LA effects on IgE signaling. First, PMCs were incubated
overnight with IgE and then treated with either media alone, 12.5 mM LA, or 12.5 mM
sodium lactate (NaLA). After treatment for 24 hours, PMC were activated with antigen
for 16 hours, and supernatants were analyzed via ELISA. Figure 4.9A shows that while
LA suppressed IgE-mediated TNF secretion, NaLA did not affect TNF secretion relative
to media alone. This shows that LA suppresses in a pH-dependent manner. To determine
if the effect of LA is MCT-1-dependent, PMCs were first incubated overnight with IgE
and then treated with an inhibitor of MCT-1 and MCT-2, AR-C155858. Since we
previously found that mast cell do not to express MCT2, any changes with AR-C155858
would be due to MCT-1 (158). After 1-hour incubation with vehicle (DMSO) or ARC155858, PMC were treated with media alone or 12.5 mM LA for 24 hours, then
activated for 16 hours with antigen and analyzed via ELISA. Figure 4.9B shows that in
the vehicle alone group, LA suppressed IgE-mediated secretion of TNF as expected.
Howvere, in the presence of AR-C155858 LA no longer decreased TNF secretion. We
concluded that, as with IL-33, LA suppresses IgE-mediated mast cell activation in a pHand MCT-1-dependent manner.
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FIGURE 4.9. LA suppress IgE-mediated cytokine production in a pH- and MCT-1dependent manner A) PMC were treated with either 12.5 mM LA or 12.5 mM sodium
lactate for 24 hours and then activated via IgE-Ag crosslinking. B) PMC were pre-treatd
with either an MCT-1/2 inhibitor AR-C155858 (100 nM) or DMSO (vehicle) for 1 hour,
treated with 12.5 mM for 24 hours, and then activated via IgE-Ag crosslinking. 16 hours
later supernatants were collected and analyzed via ELISA. Results are two experiments
conducted in triplicate and expressed as mean ±SEM.*, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001; N.S., not significant.
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IV.4.9 LA alters IgE-mediated signaling
To better understand how LA alters IgE-mediated responses in mast cells, IgE
signaling was analyzed in the presence of LA. PMC were incubated overnight with IgE
then treated with either media alone or 12.5 mM LA for 24 hours. DNP-HSA was used to
activate PMC. 5 minutes after activation, cells were fixed using methanol, permeabilized
with 1.6% paraformaldehyde, and stained using antibodies against phospho-Syk,
phospho-Btk, and phospho-ERK1/2 before flow cytometry analysis. Figure 4.10
demonstrates that LA treatment reduces phosphorylation of Syk, Btk, and ERK 1/2,
showing that LA does in fact alter IgE signaling events. The suppression of Syk
phosphorylation is noteworthy because in Syk-deficient mast cells, IgE-mediated
degranulation, calcium flux, and cytokine production are abolished (153, 159). In
conclusion, LA suppresses the activation of key signaling proteins in the IgE signaling
cascade.
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FIGURE 4.10. LA alters IgE-mediated signaling PMC were given IgE overnight and
then treated with 12.5 mM LA for 24 hours. During those last 4 hours, PMC were starved
from IL-3 and SCF. Cells were then given Ag (50 ng/mL) to induce activation via IgEAg crosslinking. 10 minutes after activation, cells were fixed and permeabilized, stained
for phosphorylation of key signaling mediators of the IgE signaling pathway, and run on
the FACSCelesta and analyzed for changes in phosphorylation levels. Results are three
experiments conducted in triplicate and expressed as mean ±SEM.*, p<0.05; **, p<0.01;
***, p<0.001; ****, p<0.0001; N.S., not significant.
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IV.4.10 LA alters passive systemic anaphylaxis
Lastly, we wanted determined if LA alters IgE-mediated mast cell responses in
vivo. Therefore, we used the mast cell-mediated PSA model. C57BL/6 mice were
injected with IgE, and the next day injected first with ketoprofen to alleviate pain
associated with LA, and then either PBS or LA at 4mg/kg. 24 hours after PBS or LA
injections, mice were injected with antigen to induce anaphylaxis. Core body temperature
was measured over the course of 2 hours using a rectal probe. Figure 4.11 shows that
mice receiving LA underwent less severe anaphylaxis based on core body temperature
change. Because this is both a mast cell- and histamine-dependent model, it is possible
that LA changed vasculature responsiveness to histamine, and not mast cell behavior
(154). Therefore, we conducted another PSA study in which we induced anaphylaxis with
histamine injections, rather than IgE and antigen, after injecting mice with either PBS or
LA. In histamine-induced PSA, there was no difference in temperature drop between
mice that received PBS or LA, indicating no changes in the responsiveness of the
endothelium to histamine. This demonstrates that LA can functionally alter mast cell IgEmediated behavior in vivo.
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FIGURE 4.11. LA alters passive systemic anaphylaxis Age-matched C57BL/6 mice
were first subcutaneously injected with ketoprofen, 30 minutes later intraperitoneally
injected with LA, 24 hours later intraperitoneally injected with IgE (50 μg), and then 16
hours later injected with Ag (100 μg) to induce passive systemic anaphylaxis. Histamineinduced passive systemic anaphylaxis was done by intraperitoneally injecting 8 mg of
histamine, rather than IgE and Ag. Results shown are from 5 mice in each group and
expressed as mean ±SEM.*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; N.S., not
significant.
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IV.5 DISCUSSION
In this study, LA was shown to alter IgE-mediated activation, with variable
effects based on the source of mast cells used. We initially showed that LA enhanced
cytokine production from BMMC. This enhancement included several inflammatory
cytokines: TNF, IL-6, MCP-1, MIP-1α, and IL-13, as well as VEGF. An in vitro
angiogenesis assay demonstrated showed that LA-treated, IgE-activated BMMC secreted
pro-angiogenic factors, as tube formation was dramatically increased. While we have
detected VEGF, our current experiments does not prove that VEGF is required for the
angiogenic activity, and we suspect other pro-angiogenic mediators are enhanced by LA
treatment. This is in keeping with prior papers showing angiogenic factors produced by
mast cells (40, 46, 160). Further investigation will be necessary to determine how LA
alters the expression of these other angiogenic factors in the context of IgE crosslinking.
The mechanism by which VEGF is induced in mast cells is still being elucidated, but a
Fyn-dependent mechanism has been reported (44). Additionally, more recent work has
shown that IgE-mediated mast cell production of leukotriene B4 and 12(S)hydroxyeicosatetraenoic acid, ligands of leukotriene B4 receptor 2 (BLT2), play a critical
role in VEGF production. BLT2 ligands are produced in response to IgE crosslinking, nd
appear to provide positive feedback via BLT2, promoting VEGF synthesis (161). These
provide new targets in studying how LA enhances IgE-mediated VEGF production.
We demonstrated the ability of LA to reduce activation of key signaling
molecules in the IgE signaling cascade: Syk, Btk, and ERK. Syk activation is a critical,
apical transducer of FceRI signaling, driving degranulation, calcium flux, and cytokine
production (153, 159). By nature of working with a populations where relatively few
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cells are obtained from tissue harvesting, measuring changes in cell signaling proteins is
challenging with PMC. For this reason we employed flow cytometry versus western
blotting (162). This limited our analyses, due to reagent availability. Thus it will be
important to expand this study to further explore how LA alters IgE-mediated signaling
in PMCs.
When expanding our studies beyond BMMC to PMC and SkMC, an unexpected
response occurred. While LA enhanced IgE-mediated cytokines with BMMC, it
suppressed this response in PMC and SkMC. These discrepancies in response to LA
might be attributed to mast cell heterogeneity. In the mouse system, mast cells are
divided into mucosal mast cells (MMC) and connective tissue mast cells (CTMC),
whereas in the human system mast cells are divided based on the their granular contents.
Human mast cells with granules containing proteases that are mostly tryptases are
referred to as mast cell tryptase (MCT), and mast cells expressing both chymases and
tryptases are referred to as mast cell tryptase-chymase (MCTC). Based on granular
content, the mouse mucosal mast cell is analogous to the human MCT, and the mouse
connective tissue mast cell to the human MCTC. The PMC used in this work are CTMC,
and the human SkMCs are the analogous MCTC (60, 163, 164). In contrast, the BMMC
used more closely resemble MMC (165). Thus lineage-specific effects may explain the
differences in our results. This is supported by recent work demonstrating that the
heterogenic differences in mast cell populations can lead to divergent expression profiles
(57). However, it is important to note that BMMC are differentiated in vitro, while PMC
and SkMC differentiate in vivo and expand ex vivo. For these reasons, we place a greater
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emphasis on results from PMC and SkMC studies. Future work will include assessing the
response of in vivo-derived MMC, to further assess lineage-specific effects.
The ability of LA to suppress IgE-mediated responses was further validated by the
results of the in vivo PSA experiment, where mice injected with LA had a reduced
temperature drop, indicating that those mice underwent less severe anaphylaxis. Mice
injected with LA showed no difference compared to mice injected with PBS when
undergoing histamine-induced PSA, demonstrating that LA is not acitng on the
endothelium but rather suppressing IgE- and mast cell-mediated responses in vivo.

IV.6 CONCLUSION
In this study we demonstrate that LA enhances IgE-mediated cytokine production
by BMMC. This enhancement includes VEGF, which correlated with angiogenic effects
in an in vitro assay. Interestingly, when mast cells were sourced from either the
peritoneum of mice or from skin biopsies from human donors, LA suppressed IgEmediated cytokine production. Given that these two mast cell populations matured in
vivo, they are of greater physiological relevance and PMCs were used throughout the rest
of the study. While LA suppressed IgE-mediated inflammatory cytokine production in
PMCs, VEGF secretion was still enhanced. LA-mediated suppression of IgE crosslinked
PMCs was shown to be pH- and MCT-1-dependent. Additionally, LA suppressed the
phosphorylation of Syk, Btk, and ERK, key mediators in IgE signaling. Lastly, LA was
able to suppress IgE and mast cell-mediated responses in vivo, reducing the temperature
drop in passive systemic anaphylaxis. Collectively, these data demonstrate that LA to
promotes an anti-inflammatory and pro-angiogenic phenotype in mast cells.
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CHAPTER V: CONCLUSIONS AND FUTURE
WORK
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V.I SUMMARY
Mast cells are a tissue resident cell population of the innate immune system that
have been shown to play a critical role in inflammatory responses to biomaterials.
Improving biomaterial design is critical to overcoming fibrotic responses for many
implants. Previous work demonstrated how increasing scaffold pore size is needed for
promoting improved tissue integration, as well as reducing macrophage M1 polarization.
However little work has explored how biomaterials can be manipulated to alter mast cell
responses, particularly with regard to scaffold architecture and degradative byproducts.
In Chapter 2, IL-33- and LPS-mediated cytokine and chemokine production was
measured from BMMC cultured on electrospun polydioxanone of varying geometries.
First, the two electrospun scaffolds used were a 60 mg/mL scaffold and a 140 mg/mL
scaffold, where the 140 mg/mL scaffold had larger pore and fiber diameters. In response
to IL-33 and LPS, BMMC cultured on the 140 mg/mL scaffold had reduced IL-6, TNF,
MCP-1, and MIP-1α secretion but enhanced VEGF secretion, when compared to the
60mg/mL scaffold. This pro-angiogenic phenotype was also true at the mRNA level,
where in response to IL-33, BMMC cultured on the 140 mg/mL scaffold showed greater
VEGF and MMP-9 expression. When trying to isolate the role of scaffold pore size, 60
mg/mL polydioxanone scaffolds were electrospun on an air-flow mandrel. In response to
this increased pore size, LPS- and IL-33-mediated IL-6 and TNF production were
dramatically reduced. Interestingly, reducing pore size of 140 mg/mL scaffolds using a
hydraulic press only partially reduced IL-33- and LPS-mediated inflammatory cytokine
production. Together these data emphasize the importance of pore dimension, but also
suggest that larger fibers are less inflammatory and less dependent on pore size. These
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data can help guide design of implanted materials to promote wound healing and reduce
inflammation and chronic fibrosis.
In Chapter 3, we explored how degradative byproducts of synethetic polymers
could alter also alter IL-33-mediated mast cell activation. We did this by pre-treating
BMMC with LA that were then activated with IL-33. LA pre-treatment suppressed
inflammatory cytokine and chemokine production while enhancing VEGF, a phenotype
that mimics what we saw in Chapter 2 with scaffolds of increased pore size. Changes in
IL-33-meidated cytokine production were also true of ex vivo-derived peritoneal mast
cells. These effects were pH- and MCT-1-dependent, and selectively suppressed key
proteins involved in IL-33 signaling. The enhancement of VEGF was shown to be Akt1dependent based on siRNA experiments.
LA treatment enhanced HIF-1α expression which we found to negatively regulate
miR-155-5p levels. Further, LA-mediated suppression of IL-33-induced cytokine
production required miR-155-5p suppression, since miR-155-5p overexpression reversed
LA effects. Because miR-155-5p promotes inflammation, LA-mediated miR-155-5p
suppression corroborates the proposed anti-inflammatory role for LA. Furthermore, these
data were consistent in vivo. LA injection reduced the stimulatory effects of IL-33 on
plasma cytokine levels. Lastly, skin mast cells from human donors showed that LA
abolished the ability of IL-33 to enhance IgE-mediated cytokine production, an effect
shown to be MCT-dependent. These data suggest that LA, an important degradative byproduct of PLLA polymers, suppresses IL-33-mediated pro-inflammatory cytokines
while promoting angiogenic factor secretion.
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Given how potent IgE crosslinking is in activating mast cells, as well as the
ability of IgE crosslinking to potentiate inflammation and angiogenesis, the work in
Chapter 4 explored how LA alters IgE signaling in mast cells. We were surprised to find
that, when added to BMMC cultures, LA enhanced IgE-mediated inflammatory cytokine
production, as well as VEGF secretion. Supernatants from these cultures promoted robust
endothelial cell tube formation, confirming LA promotes an angiogenic phenotype in
mast cells. Investigating the effects of LA on IgE crosslinked mast cells was extended to
include peritoneal mast cells and human skin mast cells. These experiments demonstrated
inhibitory effects of LA, consistent with our IL-33 studies. LA similarly reduced the
severity of IgE- and mast cell-mediated passive systemic anaphylaxis in vivo. We
concluded that there may be lineage- or culture-dependent effects, and that on balance,
LA effects are largely anti-inflammatory. Using peritoneal mast cells, we determined that
the ability of LA to suppress IgE-mediated cytokine production was pH- and MCT-1dependent and not due to changes in surface expression of the IgE receptor FcεRI. Lastly,
LA reduced activation of key IgE signaling molecules, including Syk, Btk, and ERK.
Collectively LA appears to be a potent suppressor of mast cell inflammatory responses,
while promoting angiogenesis. These properties, along with knowledge of
spatial/structural considerations, provide insight for designing biologically useful
polymers.

V.II FUTURE WORK
The work done in Chapter 2 would be better served by conducting several more
experiments. In order to better understand the mechanism by which scaffold structure
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alters IL-33- and LPS-mediated responses, measuring changes in signaling via flow
cytometry would be helpful. Trying to measure changes in signaling events proved to be
difficult using western blotting, and flow cytometry provides the advantage of being
more high-throughput and requiring fewer cells. Another productive experiment would
be to determine if scaffold structural changes lead alter mast cell responses at the
transcriptional level, particularly for AP-1 and NF-kB, which are critical for IL-33 and
LPS effects. Lastly, another future experiment would include subcutaneously implanting
60 and 140 mg/mL polydioxanone scaffolds into C57BL/6 mice. After 4 weeks, mice
would be perfused with a contrast agent (e.g. Microfil) and changes in the local
vasculature would be measured using microCT. Additionally, scaffolds would be excised
and analyzed histologically for fibrous capsule formation and macrophage polarization.
The role of mast cells would be determined by including mast cell-deficient KitW-sh/W-sh
mouse.
While the LA and IL-33 story is more complete, there are still questions left to be
answered. We need to determine what miR-155 is targeting in this system. One way to
find out would be to mine through different software algorithms, such as the DIANA
micro-T tool, that assist in identifying targets based on the miR recognition elements that
are validated experimentally. Once a target is identified, we can measure its expression in
the presence of LA, and then knockdown expression of that target using siRNAs to
determine if it is a necessary component for LA effects. Additionally, an important
experiment to conduct would also be to electrospin poly-lactic acid scaffolds, incubate
them in media to allow for scaffold degradation over time, and treat mast cells with that
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conditioned media to determine if this alters IL-33- or IgE-mediated activation of mast
cells.
Future work with LA and IgE-activated mast cells would include repeating the in
vitro angiogenesis experiment with conditioned supernatants from IgE-crosslinked PMC,
since LA suppressed inflammatory cytokine production in these cells. While VEGF was
enhanced, it would be helpful to confirm if LA promoted a functional angiogenic
phenotype with the PMC as well. Lastly, given that PMC and SkMC, considered to be
connective tissue mast cells, responded to LA differently than BMMC, a mucosal mast
cell, it would be important to use a mucosal mast cell that matured in vivo and determine
if their response to LA mimics the BMMC.

V. CONCLUDING REMARKS
In summary, this work demonstrates that altering scaffold structure alters mast
cell inflammatory and angiogenic responses. Additionally, the degradative byproducts of
synthetic polymers from biomaterials can also dictate inflammatory and angiogenic
responses. Mast cell responses to biomaterials warrants further investigation, particularly
in the presence of signals like IL-33. Hopefully this work will help shed light on how to
improve biomaterial design to mitigate inflammation and promote wound healing.
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